anti-mitochondrial, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, anti-mitochondrial

Abbasciano V, Trevisani L, Di Todaro F, Guglielmini C, Marzola A, Sartori S, Salemi A 2006 Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome. An early case. Recenti. Prog. Med. 97: 28-31.
Abedi MR, Hammarstrom L, Broome U, Angelin B, Smith CI, Christensson B 1996 Reduction in serum levels of antimitochondrial (M2) antibodies following immunoglobulin therapy in severe combined immunodeficient (SCID) mice reconstituted with lymphocytes from patients with primary biliary cirrhosis (PBC). Clin. Exp. Immunol. 105: 266-273. *
Adachi M, Ishii H 2002 Role of mitochondria in alcoholic liver injury. Free Radic. Biol. Med. 32: 487-491.
Adami P, Berrez JM, Latruffe N 1991 Mitochondrial pyruvate dehydrogenase complex subunits as autoantigens in human primary biliary cirrhosis. Biochem. Int. 23: 429-437.
Adams JS, Chen H, Chun R, Ren S, Wu S, Gacad M, Nguyen L, Ride J, Liu P, Modlin R, Hewison M 2007 Substrate and enzyme trafficking as a means of regulating 1,25-dihydroxyvitamin D synthesis and action: the human innate immune response. J. Bone Miner. Res. 22 Suppl. 2: V20-V24.
Agarwal A, Makker K, Sharma R 2008 Clinical relevance of oxidative stress in male factor infertility: an update. Am. J. Reprod. Immunol. 59: 2-11. *
Agarwal K, Jones DE, Watt FE, Burt AD, Floreani A, Bassendine MF 2002 Familial primary biliary cirrhosis and autoimmune cholangitis. Dig. Liver Dis. 34: 50-52.
Akiyama Y, Tanaka M, Takeishi M, Adachi D, Mimori A, Suzuki T 2000 Clinical, serological and genetic study in patients with CREST syndrome. Intern. Med. 39: 451-456. *
Al Hussami O, Godinot C, Monier JM, Trepo C, Monier JC 1986 Demonstration of anti-mitochondria antibodies by ELISA. Comparison with the indirect immunofluorescence technique on organ sections. J. Clin. Lab. Immunol. 21: 195-199.
al-Hussami O, Godinot C, Monier JM, Trepo C, Monier JC 1988 Use of immunoblotting to characterize the mitochondrial antigens recognized by anti-mitochondrial autoantibodies. J. Immunol. Methods 113: 61-73.
Al-Jabri AA, Al Belushi MS, Nsanze H 2003 Frequency and levels of autoantibodies in healthy adult Omanis. Ann. Saudi Med. 23: 372-375.
Alard JE, Dueymes M, Youinou P, Jamin C 2007 Modulation of endothelial cell damages by anti-Hsp60 autoantibodies in systemic autoimmune diseases. Autoimmun. Rev. 6: 438-443.
Alderuccio F, Toh BH, Barnett AJ, Pedersen JS 1986 Identification and characterization of mitochondria autoantigens in progressive systemic sclerosis: identity with the 72,000 dalton autoantigen in primary biliary cirrhosis. J. Immunol. 137: 1855-1859.
Alessandri C, Sorice M, Bombardieri M, Conigliaro P, Longo A, Garofalo T, Manganelli V, Conti F, Esposti ED, Valesini G 2006 Anti-phospholipid reactivity against cardiolipin metabolites occurring during endothelial cell apoptosis. Arthritis Res. Ther. 8: R180. *
Allina J, Hu B, Sullivan DM, Fiel MI, Thung SN, Bronk SF, Huebert RC, van de Water J, LaRusso NF, Gershwin ME, Gores GJ, Odin JA 2006 T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J. Autoimmun. 27: 232-241.
Alric L, Thebault S, Selves J, Peron JM, Mejdoubi S, Fortenfant F, Vinel JP 2007 Characterization of overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis according to antimitochondrial antibodies status. Gastroenterol. Clin. Biol. 31: 11-16. *
Amakasu H, Kanno A, Abe M 1993 Multiple myeloma occurring in early stage primary biliary cirrhosis. Tohoku J. Exp. Med. 169: 197-203.
Amano K, Leung PS, Xu Q, Marik J, Quan C, Kurth MJ, Nantz MH, Ansari AA, Lam KS, Zeniya M, Coppel RL, Gershwin ME 2004 Xenobiotic-induced loss of tolerance in rabbits to the mitochondrial autoantigen of primary biliary cirrhosis is reversible. J. Immunol. 172: 6444-6452. *
Ambinder EP, Cohen LB, Wolke AM, Field SP, Adelsberg B, Schaffner F, Zaroulis CG 1985 The clinical effectiveness and safety of chronic plasmapheresis in patients with primary biliary cirrhosis. J. Clin. Apheresis 2: 219-223.
Amezcua-Guerra LM, Prieto P, Bojalil R, Pineda C, Amigo MC 2006 Microscopic polyangiitis associated with primary biliary cirrhosis: a causal or casual association? J. Rheumatol. 33: 2351-2353.
Anand AC, Elias E, Neuberger JM 1996 End-stage primary biliary cirrhosis in a first generation migrant south Asian population. Eur. J. Gastroenterol. Hepatol. 8: 663-666.
Anderson CD, Pierce J, Nicoud I, Belous A, Knox CD, Chari RS 2005 Modulation of mitochondrial calcium management attenuates hepatic warm ischemia-reperfusion injury. Liver Transpl. 11: 663-668. *
Andre J, Cimaz R, Ranchin B, Galambrun C, Bertrand Y, Bouvier R, Rieux-Laucat F, Trescol-Biemont MC, Cochat P, Bonnefoy-Berard N 2007 Overexpression of the antiapoptotic gene Bfl-1 in B cells from patients with familial systemic lupus erythematosus. Lupus 16: 95-100.
Angulo P 2002 Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 4: 37-44.
Antonio Olivera M, Zapata L, Kaplan M, Bobadilla J, Corte G, de la Mora G, Uribe M, Cabiedes J, Dehesa M, Kershenobich D 1993 Prevalence of antinuclear antibodies in primary biliary cirrhosis, with negative antimitochondrial antibodies. Rev. Gastroenterol. Mex. 58: 220-222.
Antunes F, Boveris A, Cadenas E 2004 On the mechanism and biology of cytochrome oxidase inhibition by nitric oxide. Proc. Natl. Acad. Sci. U.S.A. 101: 16774-16779. *
Aoki A, Kirino Y, Ishigatsubo Y, Senuma A, Nagaoka S 2004 Liver involvement in primary Sjogren's syndrome. Nihon Rinsho Meneki Gakkai Kaishi 27: 397-401.
Arbour L, Rupps R, Field L, Ross P, Erikson A, Henderson H, Hill W, Yoshida E 2005 Characteristics of primary biliary cirrhosis in British Columbia's First Nations population. Can. J. Gastroenterol. 19: 305-310.
Arcavi M, Orfus G 2006 Prevalence of antinuclear envelope antibodies and their isotypes in sera positive for antinuclear antibodies. Medicina (B. Aires) 66: 327-331.
Archimandritis A, Tjivras M, Tsirantonaki M, Hatzis G, Delladetsima I 1995 Sjogren's syndrome with antimitochondrial antibody-negative primary biliary cirrhosis: a case of autoimmune cholangitis. J. Clin. Gastroenterol. 20: 268-270.
Arcos-Burgos M, Palacio LG, Mora O, Sanchez JL, Jimenez M, Jimenez I 2000 Molecular genetic aspects of the susceptibility to develop idiopathic epilepsy. Rev. Neurol. 30: 173-177.
Arundel C, Lewis JH 2007 Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244-254.
Arya R, Mallik M, Lakhotia SC 2007 Heat shock genes - integrating cell survival and death. J. Biosci. 32: 595-610. *
Atzeni F, Doria A, Ghirardello A, Villalta D, Zampieri S, Carrabba M, Sarzi-Puttini P 2008 Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. Autoimmunity 41: 87-91.
Avigan MI, Adamson G, Hoofnagle JH, Jones EA 1986 The in vitro production of antibodies to mitochondrial antigens by peripheral blood mononuclear cells from patients with primary biliary cirrhosis. Hepatology 6: 999-1004.
Azzaroli F, Mehal W, Soroka CJ, Wang L, Lee J, Crispe N, Boyer JL 2002 Ursodeoxycholic acid diminishes Fas-ligand-induced apoptosis in mouse hepatocytes. Hepatology 36: 49-54. *
Babb RR 1992 Chronic liver disease. The scope of causes and treatments. Postgrad. Med. 91: 89-96.
Bajt ML, Ho YS, Vonderfecht SL, Jaeschke H 2002 Reactive oxygen as modulator of TNF and Fas receptor-mediated apoptosis in vivo: studies with glutathione peroxidase-deficient mice. Antioxid. Redox Signal. 4: 733-740.
Balan V, Batts KP, Porayko MK, Krom RA, Ludwig J, Wiesner RH 1993 Histological evidence for recurrence of primary biliary cirrhosis after liver transplantation. Hepatology 18: 1392-1398.
Balistreri WF 2003 Genetic liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases.
Bandin O, Courvalin JC, Poupon R, Dubel L, Homberg JC, Johanet C 1996 Specificity and sensitivity of gp210 autoantibodies detected using an enzyme-linked immunosorbent assay and a synthetic polypeptide in the diagnosis of primary biliary cirrhosis. Hepatology 23: 1020-1024. *
Bar-Dayan Y, Gershwin ME, Levi Y, Amital H, Shoenfeld Y 1998 Primary biliary cirrhosis. Is (and how much of) the pathology preventible? Immunol. Res. 18: 117-123.
Bargou I, Mankai A, Jamaa A, Ben Jazia I, Skandrani K, Sfar H, Baccouche A, Ajmi S, Letaief A, Fabien N, Jeddi M, Ghedira I 2008 Detection of M2 antimitochondrial antibodies by dot blot assay is more specific than by enzyme linked immunosorbent assay. Pathol. Biol. (Paris) 56: 10-14.
Barnes DS 2002 Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm.
Bassendine MF 2004 Infectious etiology of primary biliary cirrhosis (PBC). Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 45-46. *
Bassendine MF, Jones DE, Yeaman SJ 1997 Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Semin. Liver Dis. 17: 49-60.
Batts KP, Wang X 1998 Recurrence of primary biliary cirrhosis, autoimmune cholangitis and primary sclerosing cholangitis after liver transplantation. Clin. Liver Dis. 2: 421-435, xi.
Bauer A, Habior A 2007 Measurement of gp210 autoantibodies in sera of patients with primary biliary cirrhosis. J. Clin. Lab. Anal. 21: 227-231.
Bauerova K, Kucharska J, Mihalova D, Navarova J, Gvozdjakova A, Sumbalova Z 2005 Effect of coenzyme Q(10) supplementation in the rat model of adjuvant arthritis. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc. Czech. Repub. 149: 501-503.
Baum H 1995 Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochim. Biophys. Acta 1271: 111-121.
Bayat A, Walter J, Lambe H, Watson JS, Stanley JK, Marino M, Ferguson MW, Ollier WE 2005 Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast. Reconstr. Surg. 115: 134-141.
Bean P, Sutphin MS, Liu Y, Anton R, Reynolds TB, Shoenfeld Y, Peter JB 1995 Carbohydrate-deficient transferrin and false-positive results for alcohol abuse in primary biliary cirrhosis: differential diagnosis by detection of mitochondrial autoantibodies. Clin. Chem. 41: 858-861.
Beckebaum S, Cicinnati V, Broelsch CE 2003 Liver transplantation, rejection and disease recurrence. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 55-56. October 15-16. *
Beleznay Z, Regenass S 2008 Diagnostics of autoimmune diseases. Ther. Umsch. 65: 529-537.
Bensa C, Boscagli A, Bourg V, Bensaken S, Chanalet S, Lebrun C 2005 Recurrent aseptic meningitis associated with primary biliary cirrhosis. Rev. Neurol. (Paris) 161: 87-91.
Benson GD, Kikuchi K, Miyakawa H, Tanaka A, Watnik MR, Gershwin ME 2004 Serial analysis of antimitochondrial antibody in patients with primary biliary cirrhosis. Clin. Dev. Immunol. 11: 129-133. *
Berg CP, Stein GM, Klein R, Pascu M, Berg T, Kammer W, Priemer M, Nordheim A, Schulze-Osthoff K, Gregor M, Wesselborg S, Berg PA 2006 Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. Liver Int. 26: 846-855. *
Berg PA, Binder T, Lindner H, Bannaski H, Maas D, Henning H, Brugel H 1975 Heterogenicity of mitochondrial antibodies. Dtsch. Med. Wochenschr. 100: 1123-1127.
Berg PA, Doniach D, Roitt IM 1967 Mitochondrial antibodies in primary biliary cirrhosis. I. Localization of the antigen to mitochondrial membranes. J. Exp. Med. 126: 277-290.
Berg PA, Klein R 1992 Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig. Dis. 10: 85-101.
Berg PA, Klein R 1987 Immunology of primary biliary cirrhosis. Baillieres Clin. Gastroenterol. 1: 675-706.
Berg PA, Klein R 1992 Antimitochondrial antibodies in primary biliary cirrhosis. A clue to its etiopathogenesis? J. Hepatol. 15: 6-9.
Berg PA, Klein R 1989 Heterogeneity of antimitochondrial antibodies. Semin. Liver Dis. 9: 103-116.
Berg PA, Klein R 1995 Mitochondrial antigen/antibody systems in primary biliary cirrhosis: revisited. Liver 15: 281-292.
Berg PA, Klein R 1986 Mitochondrial antigens and autoantibodies: from anti-M1 to anti-M9. Klin. Wochenschr. 64: 897-909.
Berg PA, Klein R 2002 Autoimmune hepatitis and overlap syndrome: diagnosis. Schweiz. Rundsch. Med. Prax. 91: 1339-1346.
Berg PA, Klein R, Lindenborn-Fotinos J 1986 Antimitochondrial antibodies in primary biliary cirrhosis. J. Hepatol. 2: 123-131.
Berg PA, Klein R, Lindenborn-Fotinos J, Kloppel W 1982 ATPase-associated antigen (M2): marker antigen for serological diagnosis of primary biliary cirrhosis. Lancet 2: 1423-1426.
Berg PA, Muscatello U, Doniach D, Roitt IM 1968 Demonstration of antibodies against the inner mitochondrial membrane in the serum of patients with primary biliary liver cirrhosis. Verh. Dtsch. Ges. Inn. Med. 74: 527-529.
Berg PA, Muscatello U, Horne RW, Roitt IM, Doniach D 1969 Mitochondrial antibodies in primary biliary cirrhosis. II. The complement fixing antigen as a component of mitochondrial inner membranes. Br. J. Exp. Pathol. 50: 200-208.
Berg PA, Wiedmann KH, Sayers T, Kloppel G, Lindner H 1980 Serological classification of chronic cholestatic liver disease by the use of two different types of antimitochondrial antibodies. Lancet 2: 1329-1332.
Bergasa NV 1998 Primary biliary cirrhosis in patients with breast cancer: studying the link. Med. Hypotheses 50: 465-472.
Bergasa NV, Mason A, Floreani A, Heathcote J, Swain MG, Jones DE, Lindor KM, Bassendine MF, Worman HJ 2004 Primary biliary cirrhosis: report of a focus study group. Hepatology 40: 1013-1020. *
Berthiaume F, MacDonald AD, Kang YH, Yarmush ML 2003 Control analysis of mitochondrial metabolism in intact hepatocytes: effect of interleukin-1beta and interleukin-6. Metab. Eng. 5: 108-123. *
Beuers U 2006 Mechanisms of action of ursodeoxycholic acid for treatment of primary sclerosing cholangitis. Falk Workshop "Primary Sclerosing Cholangitis: Complications and Consequences", Moscow (Russia), June 11, 2006, p. 12. *
Beuers U, Rust C 2005 Overlap syndromes. Semin. Liver Dis. 25: 311-320.
Bianchi FB, Muratori L 2000 Primary and secondary autoimmunity in hepatology. Ann. Ital. Med. Int. 15: 56-62.
Biasi D, Caramasch P, Carletto A, Casaril M, Colombari R, Zeminian S, Bambara LM 1997 Sjogren's syndrome associated with autoimmune hepatitis. A case report. Clin. Rheumatol. 16: 409-412.
Bittencourt PL, Farias AQ, Abrantes-Lemos CP, Goncalves LL, Goncalves PL, Magalhaes EP, Carrilho FJ, Laudanna AA, Cancado EL 2004 Prevalence of immune disturbances and chronic liver disease in family members of patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 19: 873-878. *
Bizzaro N, Tampoia M, Villalta D, Platzgummer S, Liguori M, Tozzoli R, Tonutti E 2006 Low specificity of anti-tissue transglutaminase antibodies in patients with primary biliary cirrhosis. J. Clin. Lab. Anal. 20: 184-189.
Bjorkland A, Loof L, Mendel-Hartvig I, Totterman TH 1994 Primary biliary cirrhosis. High proportions of B cells in blood and liver tissue produce anti-mitochondrial antibodies of several Ig classes. J. Immunol. 153: 2750-2757.
Bjorkland A, Mendel-Hartvig I, Nelson BD, Totterman TH 1991 Primary biliary cirrhosis (PBC): characterization of a monoclonal antibody (PBC-MoAb) having specificity identical with disease-associated autoantibodies. Scand. J. Immunol. 33: 749-753.
Bjorkland A, Totterman TH 1994 Is primary biliary cirrhosis an autoimmune disease? Scand. J. Gastroenterol. Suppl. 204: 32-39.
Black D, Bird MA, Samson CM, Lyman S, Lange PA, Schrum LW, Qian T, Lemasters JJ, Brenner DA, Rippe RA, Behrns KE 2004 Primary cirrhotic hepatocytes resist TGFbeta-induced apoptosis through a ROS-dependent mechanism. J. Hepatol. 40: 942-951. *
Blanco-Barca O, Gomez-Lado C, Rodrigo-Saez E, Curros-Novos C, Briones-Godino P, Eiris-Punal J, Castro-Gago M 2006 Pyruvate dehydrogenase deficit associated to the C515T mutation in exon 6 of the E1alpha gene. Rev. Neurol. 43: 341-345.
Blatt NB, Boitano AE, Lyssiotis CA, Opipari AW Jr, Glick GD 2008 Bz-423 superoxide signals apoptosis via selective activation of JNK, Bak, and Bax. Free Radic. Biol. Med. Aug 3 [Epub ahead of print].
Bogdanos D, Vergani D, Mieli-Vergani G 2004 Overlap syndromes from pediatrics to adulthood. J. Gastroenterol. Hepatol. 19: S284-S286. *
Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U 2008 Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J. Hepatol. 49: 466-473.
Bogdanos DP, Baum H, Butler P, Rigopoulou EI, Davies ET, Ma Y, Burroughs AK, Vergani D 2003 Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. Dig. Liver Dis. 35: 801-805.
Bogdanos DP, Baum H, Grasso A, Okamoto M, Butler P, Ma Y, Rigopoulou E, Montalto P, Davies ET, Burroughs AK, Vergani D 2004 Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J. Hepatol. 40: 31-39. *
Bogdanos DP, Baum H, Gunsar F, Arioli D, Polymeros D, Ma Y, Burroughs AK, Vergani D 2004 Extensive homology between the major immunodominant mitochondrial antigen in primary biliary cirrhosis and Helicobacter pylori does not lead to immunological cross-reactivity. Scand. J. Gastroenterol. 39: 981-987. *
Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D 2005 Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology 42: 458-465. *
Bogdanos DP, Baum H, Vergani D 2003 Antimitochondrial and other autoantibodies. Clin. Liver Dis. 7: 759-777, vi.
Bogdanos DP, Invernizzi P, Mackay IR, Vergani D 2008 Autoimmune liver serology: current diagnostic and clinical challenges. World J. Gastroenterol. 14: 3374-3387. *
Bogdanos DP, Liaskos C, Rigopoulou EI, Dalekos GN 2006 Anti-mitochondrial antibodies in patients with systemic lupus erythematosus: revealing the unforeseen. Clin. Chim. Acta 373: 183-184. *
Bogdanos DP, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, Burroughs AK, Rodes J, Vergani D 2004 Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J. Autoimmun. 22: 353-362.
Boki KA, Dourakis SP 1995 Polymyositis associated with primary biliary cirrhosis. Clin. Rheumatol. 14: 375-378.
Bonaci-Nikolic B, Andrejevic S, Radlovic N, Davidovic I, Sofronic L, Spuran M, Micev M, Nikolic MM 2007 Serological and clinical comparison of children and adults with anti-endomysial antibodies. J. Clin. Immunol. 27: 163-171. *
Bondeson J, Veress B, Lindroth Y, Lindgren S 1998 Polymyositis associated with asymptomatic primary biliary cirrhosis. Clin. Exp. Rheumatol. 16: 172-174.
Bonis PA, Kaplan M 1999 Methotrexate improves biochemical tests in patients with primary biliary cirrhosis who respond incompletely to ursodiol. Gastroenterology 117: 395-399. *
Borgaonkar MR, Morgan DG 1999 Primary biliary cirrhosis and type II autoimmune polyglandular syndrome. Can. J. Gastroenterol. 13: 767-770.
Bories C, Certin M, Lavergne A, Galian A, Godeau P, Rambaud JC 1984 Primary biliary cirrhosis and sarcoidosis. Association or unique disease? Gastroenterol. Clin. Biol. 8: 851-855.
Brailski Kh, Damianov B 1983 Primary biliary cirrhosis. Vutr. Boles. 22: 27-37.
Brenard R, Geubel AP 1991 Antimitochondrial and antinuclear antibodies in primary biliary cirrhosis: an update in relation to their biochemical characterization and clinical significance. Acta Clin. Belg. 46: 305-312.
Brentnall TA 2003 Ursodiol: good drug makes good. Gastroenterology 124: 1139-1140. *
Briand JP, Andre C, Tuaillon N, Herve L, Neimark J, Muller S 1992 Multiple autoepitope presentation for specific detection of antibodies in primary biliary cirrhosis. Hepatology 16: 1395-1403.
Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro P, Dommergues JP, Reinert P, Bernard O 2004 Features and outcome of autoimmune hepatitis type 2 presenting with isolated positivity for anti-liver cytosol antibody. Clin. Gastroenterol. Hepatol. 2: 825-830. *
Brodanova M, Perlik F 1997 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Cas. Lek. Cesk. 136: 215-220.
Brostoff JM, Rashid S, McCrea D 2008 Primary biliary cirrhosis with a normal alkaline phosphatase: a case report. Cases J. 1: 33. *
Bruggraber SF, Leung PS, Amano K, Quan C, Kurth MJ, Nantz MH, Benson GD, Van de Water J, Luketic V, Roche TE, Ansari AA, Coppel RL, Gershwin ME 2003 Autoreactivity to lipoate and a conjugated form of lipoate in primary biliary cirrhosis. Gastroenterology 125: 1705-1713. *
Brunmair B, Staniek K, Dorig J, Szocs Z, Stadlbauer K, Marian V, Gras F, Anderwald C, Nohl H, Waldhausl W, Furnsinn C 2006 Activation of PPAR-delta in isolated rat skeletal muscle switches fuel preference from glucose to fatty acids. Diabetologia 49: 2713-2722. *
Brzezinska-Kolarz B, Undas A, Dyczek A, Musial J 2001 Reynolds syndrome: the combination of scleroderma and primary biliary cirrhosis. Case report. Pol. Arch. Med. Wewn. 105: 231-234.
Bubici C, Papa S, Pham CG, Zazzeroni F, Franzoso G 2004 NF-kappaB and JNK: an intricate affair. Cell Cycle 3: 1524-1529. *
Bunn CC, McMorrow M 1995 Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anti-centromere and anti-M2 antibodies. Clin. Exp. Immunol. 102: 131-136. *
Burt AD 2004 Spectrum of liver pathology in immune mediated liver diseases. J. Gastroenterol. Hepatol. 19: S353-S355. *
Burt AD 2002 Primary biliary cirrhosis and other ductopenic diseases. Clin. Liver Dis. 6: 363-380.
Buse C, Altmann F, Amann B, Hauck SM, Poulsen Nautrup C, Ueffing M, Stangassinger M, Deeg CA 2008 Discovering novel targets for autoantibodies in dilated cardiomyopathy. Electrophoresis 29: 1325-1332.
Butler P, Hamilton-Miller J, Baum H, Burroughs AK 1995 Detection of M2 antibodies in patients with recurrent urinary tract infection using an ELISA and purified PBC specific antigens. Evidence for a molecular mimicry mechanism in the pathogenesis of primary biliary cirrhosis? Biochem. Mol. Biol. Int. 35: 473-485.
Butler P, Valle F, Hamilton-Miller JM, Brumfitt W, Baum H, Burroughs AK 1993 M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. J. Hepatol. 17: 408-414.
Caballeria L, Pares A, Rodes J 1999 Treatment of primary biliary cirrhosis. Contributions to Science 1: 79-85. *
Calabrese V, Lodi R, Tonon C, D'Agata V, Sapienza M, Scapagnini G, Mangiameli A, Pennisi G, Stella AM, Butterfield DA 2005 Oxidative stress, mitochondrial dysfunction and cellular stress response in Friedreich's ataxia. J. Neurol. Sci. 233: 145-162. *
Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL 2001 A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 96: 519-525. *
Caldwell SH, Leung PS, Spivey JR, Prindiville T, de Medina M, Saicheur T, Rowley M, Reddy KR, Coppel R, Jeffers LJ, et al 1992 Antimitochondrial antibodies in kindreds of patients with primary biliary cirrhosis: antimitochondrial antibodies are unique to clinical disease and are absent in asymptomatic family members. Hepatology 16: 899-905.
Cales P, Calot M, Voigt JJ, Oksman F, Cassigneul J, Vinel JP, Pascal JP 1983 Familial autoimmune pathology comprising 2 cases of primary biliary cirrhosis. Gastroenterol. Clin. Biol. 7: 777-784.
Calmus Y, Poupon R 1991 Ursodeoxycholic acid (UDCA) in the treatment of chronic cholestatic diseases. Biochimie 73: 1335-1338.
Caramaschi P, Biasi D, Colombatti M, Pieropan S, Martinelli N, Carletto A, Volpe A, Pacor LM, Bambara LM 2006 Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity. Rheumatol. Int. 26: 209-214. *
Carroccio A, Giannitrapani L, Soresi M, Not T, Iacono G, Di Rosa C, Panfili E, Notarbartolo A, Montalto G 2001 Guinea pig transglutaminase immunolinked assay does not predict coeliac disease in patients with chronic liver disease. Gut 49: 506-511. *
Cars O, Stenram U, Stromberg A 1975 Alpha-1-antitrypsin deficiency, mitochondrial antibodies and possible primary biliary cirrhosis. A case report and family study. Ups. J. Med. Sci. 80: 93-98.
Cassani F, Bianchi FB, Lenzi M, Volta U, Pisi E 1985 Immunomorphological characterisation of antinuclear antibodies in chronic liver disease. J. Clin. Pathol. 38: 801-805. *
Castera L, Hatzfeld-Charbonnier AS, Ballot C, Charbonnel F, Dhuiege E, Velu T, Formstecher P, Mortier L, Marchetti P 2008 Apoptosis-related mitochondrial dysfunction defines human monocyte-derived dendritic cells with impaired immuno-stimulatory capacities. J. Cell. Mol. Med. May 2 [Epub ahead of print]. *
Castro RE, Sola S, Ramalho RM, Steer CJ, Rodrigues CM 2004 The bile acid tauroursodeoxycholic acid modulates phosphorylation and translocation of Bad via phosphatidylinositol 3-kinase in glutamate-induced apoptosis of rat cortical neurons. J. Pharmacol. Exp. Ther. 311: 845-852. *
Cazanave S, Vadrot N, Tinel M, Berson A, Lett�ron P, Larosche I, Descatoire V, Feldmann G, Robin MA, Pessayre D 2008 Ibuprofen administration attenuates serum TNF-alpha levels, hepatic glutathione depletion, hepatic apoptosis and mouse mortality after Fas stimulation. Toxicol. Appl. Pharmacol. 231: 336-343.
Cecere A, Caiazzo R, Romano C, Gattoni A 1998 Primary biliary cirrhosis. Clin. Ter. 149: 143-150.
Cervio E, Volta U, Verri M, Boschi F, Pastoris O, Granito A, Barbara G, Parisi C, Felicani C, Tonini M, De Giorgio R 2007 Sera of patients with celiac disease and neurologic disorders evoke a mitochondrial-dependent apoptosis in vitro. Gastroenterology 133: 195-206. *
Cha S, Leung PS, Coppel RL, Van de Water J, Ansari AA, Gershwin ME 1994 Heterogeneity of combinatorial human autoantibodies against PDC-E2 and biliary epithelial cells in patients with primary biliary cirrhosis. Hepatology 20: 574-583.
Cha S, Leung PS, Gershwin ME, Fletcher MP, Ansari AA, Coppel RL 1993 Combinatorial autoantibodies to dihydrolipoamide acetyltransferase, the major autoantigen of primary biliary cirrhosis. Proc. Natl. Acad. Sci. U.S.A. 90: 2527-2531. *
Cha S, Leung PS, Van de Water J, Tsuneyama K, Joplin RE, Ansari AA, Nakanuma Y, Schatz PJ, Cwirla S, Fabris LE, Neuberger JM, Gershwin ME, Coppel RL 1996 Random phage mimotopes recognized by monoclonal antibodies against the pyruvate dehydrogenase complex-E2 (PDC-E2). Proc. Natl. Acad. Sci. U.S.A. 93: 10949-10954. *
Chan CY, Huang YS, Wu JC, Lu RH, Hwang SJ, Wang YJ, Lee SD 1995 Detection of antibody to M2 mitochondrial antigen in Chinese patients with primary biliary cirrhosis. Zhonghua Yi Xue Za Zhi (Taipei) 55: 214-218.
Chaouat D, Belange G, Gompel H 1994 Polymyalgia rheumatica in primary biliary cirrhosis: value of the search for antimitochondrial antibodies in rhizomelic pseudo-polyarthritis and Horton disease. Rev. Med. Interne. 15: 775-776.
Chapman RW 2003 The management of primary sclerosing cholangitis. Curr. Gastroenterol. Rep. 5: 9-17.
Charatcharoenwitthaya P, Lindor KD 2005 Current concepts in the pathogenesis of primary biliary cirrhosis. Ann. Hepatol. 4: 161-175. *
Chaturvedi RK, Flint Beal M 2008 PPAR: a therapeutic target in Parkinson's disease. J. Neurochem. 106: 506-518. *
Chaudiere J, Ferrari-Iliou R 1999 Intracellular antioxidants: from chemical to biochemical mechanisms. Food Chem. Toxicol. 37: 949-962.
Chazouilleres O, Andreani T, Legendre C, Poupon R, Darnis F 1986 Nodular regenerative hyperplasia of the liver and primary biliary cirrhosis. A fortuitous association? Gastroenterol. Clin. Biol. 10: 764-766.
Chazouilleres O, Wendum D, Serfaty L, Montembault S, Rosmorduc O, Poupon R 1998 Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 28: 296-301. *
Chen CC, Meng HC, Chang FY, Yang WG, Ng WW, Lee SD 1996 Characteristics of endoscopic retrograde cholangiopancreatogram in patients with primary biliary cirrhosis. Zhonghua Yi Xue Za Zhi (Taipei) 57: 254-259.
Chen J, Lu Y, Lee CH, Li R, Leiter EH, Mathews CE 2008 Commonalities of genetic resistance to spontaneous autoimmune and free radical-mediated diabetes. Free Radic. Biol. Med. Jul 31 [Epub ahead of print].
Chen QY, Mackay IR, Fida S, Myers MA, Rowley MJ 1998 Natural and disease associated autoantibodies to the autoantigen, dihydrolipoamide acetyltransferase, recognise different epitopes. J. Autoimmun. 11: 151-161.
Chen QY, Rowley MJ, Mackay IR 1993 Antibody to two forms of dihydrolipoamide acetyltransferase (PDC-E2) in primary biliary cirrhosis. Liver 13: 130-135.
Chen Y, Yang Y, Miller ML, Shen D, Shertzer HG, Stringer KF, Wang B, Schneider SN, Nebert DW, Dalton TP 2007 Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. Hepatology 45: 1118-1128. *
Chernev K, Bakalov V 1985 Clinical-dispensary finding of patients with primary biliary cirrhosis. Vutr. Boles. 24: 42-46.
Chester KA, Robson L, Begent RH, Pringle H, Primrose L, Talbot IC, Macpherson AJ, Owen SL, Boxer G, Malcolm AD 1990 In situ and slot hybridization analysis of RNA in colorectal tumours and normal colon shows distinct distributions of mitochondrial sequences. J. Pathol. 162: 309-315.
Chevailler A, Saint-Andre JP, Preel JL, Boyer J, Joubaud F, Hurez D 1988 Clinico-immunological profile of hepatic and extrahepatic diseases accompanied by anti-mitochondrial antibodies. Ann. Med. Interne. (Paris) 139: 19-23.
Chiang PC, Chien CL, Pan SL, Chen WP, Teng CM, Shen YC, Guh JH 2005 Induction of endoplasmic reticulum stress and apoptosis by a marine prostanoid in human hepatocellular carcinoma. J. Hepatol. 43: 679-686. *
Chien RN, Sheen IS, Chen TJ, Liaw YF 1992 A clinicopathological study in primary biliary cirrhosis. J. Formos. Med. Assoc. 91 Suppl. 2: S117-S121.
Cho DH, Choi MS, Kim DH, Kim do Y, Shim SG, Lee JH, Koh KC, Paik SW, Yoo BC, Rhee JC 2005 A prospective study on the prevalence and clinical significance of autoantibodies in patients with suspected nonalcholic fatty liver disease. Korean J. Hepatol. 11: 261-267.
Cho YJ, Han DS, Kim TY, Jang SJ, Jeon YC, Sohn JH, Lee IH, Park KN 1999 Negative conversion of antimitochondrial antibody in primary biliary cirrhosis: a case of autoimmune cholangitis. J. Korean Med. Sci. 14: 102-106.
Chon CY, Park JY 2006 Primary biliary cirrhosis. Korean J. Hepatol. 12: 364-372.
Chou MJ, Lai MY, Lee SL, Tsay GJ 1992 Reactivity of anti-mitochondrial antibodies in primary biliary cirrhosis and systemic sclerosis. J. Formos. Med. Assoc. 91: 1075-1080.
Choudhary R, Baker KM, Pan J 2008 All-trans retinoic acid prevents angiotensin II- and mechanical stretch-induced reactive oxygen species generation and cardiomyocyte apoptosis. J. Cell. Physiol. 215: 172-181. *
Chuang YH, Lian ZX, Yang GX, Shu SA, Moritoki Y, Ridgway WM, Ansari AA, Kronenberg M, Flavell RA, Gao B, Gershwin ME 2008 Natural killer T cells exacerbate liver injury in a transforming growth factor beta receptor II dominant-negative mouse model of primary biliary cirrhosis. Hepatology 47: 571-580. *
Clapham JC, Arch JR 2007 Thermogenic and metabolic antiobesity drugs: rationale and opportunities. Diabetes Obes. Metab. 9: 259-275. *
Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, De Virgiliis S, Manns MP 1997 Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J. Clin. Endocrinol. Metab. 82: 1353-1361. *
Colombato LA, Alvarez F, Cote J, Huet PM 1994 Autoimmune cholangiopathy: the result of consecutive primary biliary cirrhosis and autoimmune hepatitis? Gastroenterology 107: 1839-1843.
Comay D, Cauch-Dudek K, Hemphill D, Diamandis E, Wanless I, Heathcote EJ 2000 Are antibodies to carbonic anhydrase II specific for anti-mitochondrial antibody-negative primary biliary cirrhosis? Dig. Dis. Sci. 45: 2018-2021. *
Constantinou C, Papas A, Constantinou AI 2008 Vitamin E and cancer: an insight into the anticancer activities of vitamin E isomers and analogs. Int. J. Cancer 123: 739-752. *
Coppel RL, Gershwin ME 1995 Primary biliary cirrhosis: the molecule and the mimic. Immunol. Rev. 144: 17-49.
Coppel RL, McNeilage LJ, Surh CD, Van de Water J, Spithill TW, Whittingham S, Gershwin ME 1988 Primary structure of the human M2 mitochondrial autoantigen of primary biliary cirrhosis: dihydrolipoamide acetyltransferase. Proc. Natl. Acad. Sci. U.S.A. 85: 7317-7321. *
Courvalin JC, Worman HJ 1997 Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin. Liver Dis. 17: 79-90.
Covelli M, Favia I, Marrone M, Iannone F, Gentile A, Lastilla G, Lapadula G 2006 Cutaneous lesions as presenting symptoms of primary biliary cirrhosis: an undifferentiated connective tissue disease-like onset. Clin. Rheumatol. 25: 919-922. *
Cowell RM, Blake KR, Russell JW 2007 Localization of the transcriptional coactivator PGC-1alpha to GABAergic neurons during maturation of the rat brain. J. Comp. Neurol. 502: 1-18.
Crabb DW 1999 Pathogenesis of alcoholic liver disease: newer mechanisms of injury. Keio. J. Med. 48: 184-188.
Crippa G, Cagnoni C, Castelli A, Concesi C, Girometta S, Pancotti D, Sverzellati E, Tacchini G, Pierfranceschi MG, Carrara GC 1995 Prolonged treatment with ursodeoxycholic acid for primary biliary cirrhosis. Clin. Ter. 146: 367-372.
Crispin-Acuna JC, Remes-Troche JM, Uribe M 2007 Abnormal hepatic biochemistries and clinical liver disease in patients with primary Sjogren's syndrome. Ann. Hepatol. 6: 150-155. *
Crivellari D, Cannizzaro R, Galligioni E, Valentini M, Monfardini S, Castiglione M 1992 Adjuvant therapy for primary breast cancer in a female patient affected by autoimmune liver disease: does it cure breast cancer and primary biliary cirrhosis? Tumori. 78: 395-396.
Csepregi A, Obermayer-Straub P, Kneip S, Kayser A, Loges S, Schmidt E, Nemesanszky E, Szalay F, Manns MP, Strassburg CP 2003 Characterization of a lipoyl domain-independent B-cell autoepitope on the human branched-chain acyltransferase in primary biliary cirrhosis and overlap syndrome with autoimmune hepatitis. Clin. Dev. Immunol. 10: 173-181. *
Csepregi A, Szodoray P, Zeher M 2002 Do autoantibodies predict autoimmune liver disease in primary Sjogren's syndrome? Data of 180 patients upon a 5 year follow-up. Scand. J. Immunol. 56: 623-629. *
Cukovic-Cavka S 2003 Primary biliary cirrhosis. Acta Med. Croatica 57: 221-225.
Cuzzocrea S 2006 Role of nitric oxide and reactive oxygen species in arthritis. Curr. Pharm. Des. 12: 3551-3570.
Czaja AJ 2007 Autoimmune liver disease. Curr. Opin. Gastroenterol. 23: 255-262.
Czaja AJ 2005 Autoantibodies in autoimmune liver disease. Adv. Clin. Chem. 40: 127-164.
Czaja AJ 2006 Overlap syndrome of primary biliary cirrhosis and autoimmune hepatitis: a foray across diagnostic boundaries. J. Hepatol. 44: 251-252. *
Czaja AJ 1999 Variant forms of autoimmune hepatitis. Curr. Gastroenterol. Rep. 1: 63-70.
Czaja AJ 2006 Autoimmune hepatitis - approach to diagnosis. MedGenMed. 8: 55.
Czaja AJ, Carpenter HA, Manns MP 1993 Antibodies to soluble liver antigen, P450IID6, and mitochondrial complexes in chronic hepatitis. Gastroenterology 105: 1522-1528.
Czaja AJ, Carpenter HA, Santrach PJ, Moore SB 1996 Genetic predispositions for immunological features in chronic liver diseases other than autoimmune hepatitis. J. Hepatol. 24: 52-59. *
Czaja AJ, Manns MP, Homburger HA 1992 Frequency and significance of antibodies to liver/kidney microsome type 1 in adults with chronic active hepatitis. Gastroenterology 103: 1290-1295.
Czaja AJ, Norman GL 2003 Autoantibodies in the diagnosis and management of liver disease. J. Clin. Gastroenterol. 37: 315-329.
Czompoly T, Olasz K, Nyarady Z, Simon D, Bovari J, Nemeth P 2008 Detailed analyses of antibodies recognizing mitochondrial antigens suggest similar or identical mechanism for production of natural antibodies and natural autoantibodies. Autoimmun. Rev. 7: 463-467.
Czompoly T, Olasz K, Simon D, Nyarady Z, Palinkas L, Czirjak L, Berki T, Nemeth P 2006 A possible new bridge between innate and adaptive immunity: are the anti-mitochondrial citrate synthase autoantibodies components of the natural antibody network? Mol. Immunol. 43: 1761-1768. *
D'Amico E, Paroli M, Fratelli V, Palazzi C, Barnaba V, Callea F, Consoli G 1995 Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Dig. Dis. Sci. 40: 2113-2116.
da Rosa Utiyama SR, da Silva Kotze LM, Nisihara RM, Carvalho RF, de Carvalho EG, de Sena MG, de Messias Reason IJ 2001 Spectrum of autoantibodies in celiac patients and relatives. Dig. Dis. Sci. 46: 2624-2630. *
da Rosa Utiyama SR, Nisihara RM, Nass FR, Oliveira NP, Fiedler PT, de Messias-Reason IT 2008 Autoantibodies in patients with Down syndrome: early senescence of the immune system or precocious markers for immunological diseases? J. Paediatr. Child. Health 44: 182-186.
Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG 2003 Pediatric-onset primary biliary cirrhosis. Gastroenterology 125: 1476-1479. *
Dai Y, Liang YH, Xie PY, Chen BW, Liu XG 2005 Clinical analysis of primary biliary cirrhosis: a report of 42 cases. Beijing Da Xue Xue Bao 37: 410-414.
Das KM 2004 Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J. Gastroenterol. Hepatol. 19: S290-S294. *
Das UN 2007 A defect in the activity of Delta(6) and Delta(5) desaturases may be a factor in the initiation and progression of atherosclerosis. Prostaglandins Leukot. Essent. Fatty Acids 76: 251-268. *
Davalos M, Roman R, Bustios C, Zumaeta E, Yabar A 2004 Autoimmune hepatitis: clinical forms and related factors to their response to treatment. Rev. Gastroenterol. Peru 24: 305-313.
Davidson MH, Yannicelli HD 2006 New concepts in dyslipidemia in the metabolic syndrome and diabetes. Metab. Syndr. Relat. Disord. 4: 299-314.
Davis LM, Pei Z, Trush MA, Cheskin LJ, Contoreggi C, McCullough K, Watkins PA, Moran TH 2006 Bromocriptine reduces steatosis in obese rodent models. J. Hepatol. 45: 439-444. *
Davis PA, Leung P, Manns M, Kaplan M, Munoz SJ, Gorin FA, Dickson ER, Krawitt E, Coppel R, Gershwin ME 1992 M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena? Hepatology 16: 1128-1136.
de Giorgio R, Volta U, Stanghellini V, Cogliandro RF, Barbara G, Corinaldesi R, Towns R, Guo C, Hong S, Wiley JW 2008 Neurogenic chronic intestinal pseudo-obstruction: antineuronal antibody-mediated activation of autophagy via Fas. Gastroenterology 135: 601-609. *
Demirag MD, Goker B, Haznedaroglu S, Ozturk MA, Karakan T, Kuruoglu R 2008 Osteomalacic myopathy associated with coexisting coeliac disease and primary biliary cirrhosis. Med. Princ. Pract. 17: 425-428.
Dhote R, Christoforov B, Weill B, Menkes CJ 1995 Joint and systemic manifestations related to type 2 anti-mitochondrial antibodies. Ann. Med. Interne. (Paris) 146: 536-540.
Ding WX, Ni HM, DiFrancesca D, Stolz DB, Yin XM 2004 Bid-dependent generation of oxygen radicals promotes death receptor activation-induced apoptosis in murine hepatocytes. Hepatology 40: 403-413. *
Diu A, Moebius U, Ferradini L, Genevee C, Roman-Roman S, Claudon M, Delorme D, Meuer S, Hercend T, Praz F 1993 Limited T-cell receptor diversity in liver-infiltrating lymphocytes from patients with primary biliary cirrhosis. J. Autoimmun. 6: 611-619.
Doering J, Begue B, Lentze MJ, Rieux-Laucat F, Goulet O, Schmitz J, Cerf-Bensussan N, Ruemmele FM 2004 Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn�s disease. Gut 53: 1632-1638. *
Dohmen K, Mizuta T, Nakamuta M, Shimohashi N, Ishibashi H, Yamamoto K 2004 Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J. Gastroenterol. 10: 894-898. *
Domercq M, Sanchez-Gomez MV, Sherwin C, Etxebarria E, Fern R, Matute C 2007 System xc- and glutamate transporter inhibition mediates microglial toxicity to oligodendrocytes. J. Immunol. 178: 6549-6556. *
Douglas JG, Finlayson ND 1979 Are increased individual susceptibility and environmental factors both necessary for the development of primary biliary cirrhosis? Br. Med. J. 2: 419-420. *
Dubel L, Farges O, Bismuth H, Sebagh M, Homberg JC, Johanet C 1995 Kinetics of anti-M2 antibodies after liver transplantation for primary biliary cirrhosis. J. Hepatol. 23: 674-680. *
Dubel L, Tanaka A, Leung PS, Van de Water J, Coppel R, Roche T, Johanet C, Motokawa Y, Ansari A, Gershwin ME 1999 Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology 29: 1013-1018. *
Duclos-Vallee JC, Hadengue A, Ganne-Carrie N, Robin E, Degott C, Erlinger S 1995 Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome. Corticoresistance and effective treatment by cyclosporine A. Dig. Dis. Sci. 40: 1069-1073.
Dyroy E, Rost TH, Pettersen RJ, Halvorsen B, Gudbrandsen OA, Ueland T, Muna Z, Muller F, Nordrehaug JE, Aukrust P, Berge RK 2007 Tetradecylselenoacetic acid, a PPAR ligand with antioxidant, antiinflammatory, and hypolipidemic properties. Arterioscler. Thromb. Vasc. Biol. 27: 628-634. *
Eklund A, Stjernberg N, Uddenfeldt P, Danielsson A 1985 Kveim test and mitochondrial antibodies in the differential diagnosis between primary biliary cirrhosis and sarcoidosis. Sarcoidosis 2: 38-41.
Elias E 2004 Hepatology highlights. Hepatology 39: 1467-1468. *
Elkhalifa MY, Kiechle FL, Gordon SC, Chen J, Poulik MD 1992 A flow cytometric method to detect anti-pyruvate dehydrogenase antibody in primary biliary cirrhosis. Am. J. Clin. Pathol. 97: 202-208.
Elsakka NE, Webster NR, Galley HF 2007 Polymorphism in the manganese superoxide dismutase gene. Free Radic. Res. 41: 770-778. *
Erol A 2005 PPARalpha activators may be good candidates as antiaging agents. Med. Hypotheses 65: 35-38.
Etxagibel A, Julia MR, Brotons A, Company MM, Dolz C 2008 Drug-induced hepatitis superimposed on the presence of anti-SLA antibody: a case report. J. Med. Case Reports 2: 25. *
Fantappie O, Solazzo M, Lasagna N, Platini F, Tessitore L, Mazzanti R 2007 P-Glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines. Cancer Res. 67: 4915-4923. *
Farghali H, Masek K 1998 Immunopharmacologic agents in the amelioration of hepatic injuries. Int. J. Immunopharmacol. 20: 125-139.
Farias AQ, Goncalves LL, Bittencourt PL, De Melo ES, Abrantes-Lemos CP, Porta G, Nakhle MC, Carrilho FJ, Cancado EL 2006 Applicability of the IAIHG scoring system to the diagnosis of antimitochondrial/anti-M2 seropositive variant form of autoimmune hepatitis. J. Gastroenterol. Hepatol. 21: 887-893. *
Faust TW 2000 Recurrent primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis after transplantation. Semin. Liver Dis. 20: 481-495. *
Feinstein DL, Spagnolo A, Akar C, Weinberg G, Murphy P, Gavrilyuk V, Russo CD 2005 Receptor-independent actions of PPAR thiazolidinedione agonists: is mitochondrial function the key? Biochem. Pharmacol. 70: 177-188. *
Feist E, Brychcy M, Hausdorf G, Hoyer B, Egerer K, Dorner T, Kuckelkorn U, Burmester GR 2007 Anti-proteasome autoantibodies contribute to anti-nuclear antibody patterns on human larynx carcinoma cells. Ann. Rheum. Dis. 66: 5-11. *
Feld J, Heathcote E 2003 Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18: 1118-1128. *
Feld JJ, Meddings J, Heathcote EJ 2006 Abnormal intestinal permeability in primary biliary cirrhosis. Dig. Dis. Sci. 51: 1607-1613. *
Fellman V, Lemmela S, Sajantila A, Pihko H, Jarvela I 2008 Screening of BCS1L mutations in severe neonatal disorders suspicious for mitochondrial cause. J. Hum. Genet. 53: 554-558. *
Fernandez D, Bonilla E, Mirza N, Niland B, Perl A 2006 Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2983-2988. *
Fernandez D, Bonilla E, Phillips P, Perl A 2006 Signaling abnormalities in systemic lupus erythematosus as potential drug targets. Endocr. Metab. Immune Disord. Drug Targets 6: 305-311.
Fernandez O, Fernandez V, Martinez-Cabrera V, Mayorga C, Alonso A, Leon A, Arnal C, Hens M, Luque G, de Ramon E, Caballero A, Leyva L 2008 Multiple sclerosis in Gypsies from southern Spain: prevalence, mitochondrial DNA haplogroups and HLA class II association. Tissue Antigens 71: 426-433. *
Fernandez-Checa JC 2003 Alcohol-induced liver disease: when fat and oxidative stress meet. Ann. Hepatol. 2: 69-75. *
Fernandez-Cruz E, Bootello A, Blanco MF, Gosalvez M, Segovia de Arana JM 1976 Primary biliary cirrhosis. Study of the action of mitochondrial antibody plus complement on mitochondrial membrane functions. Allergol. Immunopathol. (Madr.) 4: 145-152.
Feuchtinger M, Dengjel J, Stevanovic S, Klein R 2004 Identification of F1-ATPse as a new target antigen of antimitochondrial antibodies (AMA) in primary biliary cirrhosis (PBC). J. Hepatol. 40 Suppl. 1: 159.
Fiducia M, Lauretta R, Lunghi R, Kyanvash S, Pallotti S 2007 Hashimoto's thyroiditis and autoimmunity parameters: descriptive study. Minerva Med. 98: 95-99.
Filipovic B, Opric M, Milicic A, Paranos S 2002 Primary biliary cirrhosis. Srp. Arh. Celok. Lek. 130: 213-216.
Findor JA, Sorda JA, Daruich JR, Manero EF 2002 Familial association in autoimmune liver disease. Medicina (B. Aires) 62: 241-244.
Flachs P, Horakova O, Brauner P, Rossmeisl M, Pecina P, Franssen-van Hal N, Ruzickova J, Sponarova J, Drahota Z, Vlcek C, Keijer J, Houstek J, Kopecky J 2005 Polyunsaturated fatty acids of marine origin upregulate mitochondrial biogenesis and induce beta-oxidation in white fat. Diabetologia 48: 2365-2375. *
Flamigni F, Stanic' I, Facchini A, Cetrullo S, Tantini B, Borz� RM, Guarnieri C, Caldarera CM 2007 Polyamine biosynthesis as a target to inhibit apoptosis of non-tumoral cells. Amino Acids 33: 197-202. *
Flannery GR, Burroughs AK, Butler P, Chelliah J, Hamilton-Miller J, Brumfitt W, Baum H 1989 Antimitochondrial antibodies in primary biliary cirrhosis recognize both specific peptides and shared epitopes of the M2 family of antigens. Hepatology 10: 370-374.
Flisiak R, Pelszynska M, Prokopowicz D, Rogalska M, Grygoruk U 2005 High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis. World J. Gastroenterol. 11: 5706-5709. *
Flisiak R, Wiercinska-Drapalo A, Prokopowicz D 2000 Antibodies against M2-antigen in differential diagnosis of primary biliary cirrhosis. Pol. Merkuriusz. Lek. 8: 373-375.
Floreani A, Baragiotta A, Leone MG, Baldo V, Naccarato R 2003 Primary biliary cirrhosis and hepatitis C virus infection. Am. J. Gastroenterol. 98: 2757-2762. *
Floreani A, Betterle C, Baragiotta A, Martini S, Venturi C, Basso D, Pittoni M, Chiarelli S, Sategna Guidetti C 2002 Prevalence of coeliac disease in primary biliary cirrhosis and of antimitochondrial antibodies in adult coeliac disease patients in Italy. Dig. Liver Dis. 34: 258-261.
Foger N, Rangell L, Danilenko DM, Chan AC 2006 Requirement for coronin 1 in T lymphocyte trafficking and cellular homeostasis. Science 313: 839-842. *
Forns X, Sanchez Tapias JM, Pares A, Llovet JM, Bruix J, Rodes J 2002 Expected developments in hepatology. Best Pract. Res. Clin. Gastroenterol. 16: 957-970. *
Foroncewicz B, Mucha K, Paczek L, Oldakowska-Jedynak U, Gornicka B, Zieniewicz K, Nyckowski P, Krawczyk M 2003 Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. Transplant. Proc. 35: 2310-2312. *
Forte M, Gold BG, Marracci G, Chaudhary P, Basso E, Johnsen D, Yu X, Fowlkes J, Bernardi P, Bourdette D 2007 Cyclophilin D inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. Proc. Natl. Acad. Sci. U.S.A. 104: 7558-7563. *
Fortun PJ, Hawkey CJ 2005 Nonsteroidal antiinflammatory drugs and the small intestine. Curr. Opin. Gastroenterol. 21: 169-175.
Franco J, Saeian K 1999 Biliary tract inflammatory disorders: primary sclerosing cholangitis and primary biliary cirrhosis. Curr. Gastroenterol. Rep. 1: 95-101.
Frazer IH, Mackay IR, Jordan TW, Whittingham S, Marzuki S 1985 Reactivity of anti-mitochondrial autoantibodies in primary biliary cirrhosis: definition of two novel mitochondrial polypeptide autoantigens. J. Immunol. 135: 1739-1745.
Fregeau DR, Davis PA, Danner DJ, Ansari A, Coppel RL, Dickson ER, Gershwin ME 1989 Antimitochondrial antibodies of primary biliary cirrhosis recognize dihydrolipoamide acyltransferase and inhibit enzyme function of the branched chain alpha-ketoacid dehydrogenase complex. J. Immunol. 142: 3815-3820.
Fregeau DR, Leung PS, Coppel RL, McNeilage LJ, Medsger TA Jr, Gershwin ME 1988 Autoantibodies to mitochondria in systemic sclerosis. Frequency and characterization using recombinant cloned autoantigen. Arthritis Rheum. 31: 386-392.
Fregeau DR, Prindiville T, Coppel RL, Kaplan M, Dickson ER, Gershwin ME 1990 Inhibition of alpha-ketoglutarate dehydrogenase activity by a distinct population of autoantibodies recognizing dihydrolipoamide succinyltransferase in primary biliary cirrhosis. Hepatology 11: 975-981.
Fregeau DR, Roche TE, Davis PA, Coppel R, Gershwin ME 1990 Primary biliary cirrhosis. Inhibition of pyruvate dehydrogenase complex activity by autoantibodies specific for E1 alpha, a non-lipoic acid containing mitochondrial enzyme. J. Immunol. 144: 1671-1676.
French MA, Bernstein RM 1987 Immunoglobulin G subclass distribution of autoantibodies in systemic sclerosis, primary biliary cirrhosis, and overlap syndromes. Ann. Rheum. Dis. 46: 436-440. *
Frezza M, Terpin MM, Peri A 1992 S-Adenosyl-L-methionine (SAMe) and its use in hepatology. Minerva Gastroenterol. Dietol. 38: 145-151.
Fruchart JC, Duriez P, Staels B 1999 Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr. Opin. Lipidol. 10: 245-257.
Fuenzalida K, Quintanilla R, Ramos P, Piderit D, Fuentealba RA, Martinez GR, Inestrosa NC, Bronfman M 2007 Peroxisome proliferator-activated receptor gamma up-regulates the Bcl-2 anti-apoptotic protein in neurons and induces mitochondrial stabilization and protection against oxidative stress and apoptosis. J. Biol. Chem. 282: 37006-37015. *
Fujikura S, Davis PA, Prindiville T, Leung P, Fox RI, Gershwin ME 1990 Sjogren's syndrome and primary biliary cirrhosis: presence of autoantibodies to purified mitochondrial 2-oxo acid dehydrogenases. J. Rheumatol. 17: 1453-1457.
Fujimoto M, Sato S, Ihn H, Tamaki T, Kikuchi K, Soma Y, Tamaki K 1996 Autoantibodies to mitochondrial 2-oxo-acid dehydrogenase complexes in localized scleroderma. Clin. Exp. Immunol. 105: 297-301. *
Fujioka S, Yamamoto K, Okamoto R, Miyake M, Ujike K, Shimada N, Terada R, Miyake Y, Nakajima H, Piao CY, Iwasaki Y, Tanimizu M, Tsuji T 2002 Laparoscopic features of primary biliary cirrhosis in AMA-positive and AMA-negative patients. Endoscopy 34: 318-321.
Fujisawa A, Kambe N, Saito M, Nishikomori R, Tanizaki H, Kanazawa N, Adachi S, Heike T, Sagara J, Suda T, Nakahata T, Miyachi Y 2007 Disease-associated mutations in CIAS1 induce cathepsin B-dependent rapid cell death of human THP-1 monocytic cells. Blood 109: 2903-2911. *
Fukushima N, Ikematsu H, Nakamura M, Matsui M, Shimoda S, Hayashida K, Niho Y, Koike K, Gershwin ME, Ishibashi H 2000 Nucleotide variations amongst V(H) genes of AMA-producing B cell clones in primary biliary cirrhosis. J. Autoimmun. 14: 247-257. *
Fukushima N, Nakamura M, Matsui M, Ikematsu H, Koike K, Ishibashi H, Hayashida K, Niho Y 1995 Establishment and structural analysis of human mAb to the E2 component of the 2-oxoglutarate dehydrogenase complex generated from a patient with primary biliary cirrhosis. Int. Immunol. 7: 1047-1055.
Fukushima N, Nalbandian G, Van De Water J, White K, Ansari AA, Leung P, Kenny T, Kamita SG, Hammock BD, Coppel RL, Stevenson F, Ishibashi H, Gershwin ME 2002 Characterization of recombinant monoclonal IgA anti-PDC-E2 autoantibodies derived from patients with PBC. Hepatology 36: 1383-1392. *
Fulop P, Derdak Z, Sheets A, Sabo E, Berthiaume EP, Resnick MB, Wands JR, Paragh G, Baffy G 2006 Lack of UCP2 reduces fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology 44: 592-601. *
Furnsinn C, Willson TM, Brunmair B 2007 Peroxisome proliferator-activated receptor-delta, a regulator of oxidative capacity, fuel switching and cholesterol transport. Diabetologia 50: 8-17. *
Furuya T, Tateishi M, Nishinarita M, Kashiwazaki S 1995 Primary biliary cirrhosis in patients with Sjogren's syndrome. Nippon Rinsho 53: 2536-2539.
Fusconi M, Baum H, Caselli A, Cassani F, Ballardini G, Lenzi M, Volta U, Zauli D, Bianchi FB 1992 Demonstration of peptide-specific and cross-reactive epitopes in proteins reacting with antimitochondrial antibodies of primary biliary cirrhosis. J. Hepatol. 15: 162-169.
Fusconi M, Ghadiminejad I, Bianchi FB, Baum H, Bottazzo GF, Pisi E 1988 Heterogeneity of antimitochondrial antibodies with the M2-M4 pattern by immunofluorescence as assessed by Western immunoblotting and enzyme linked immunosorbent assay. Gut 29: 440-447. *
Fussey SP, Ali ST, Guest JR, James OF, Bassendine MF, Yeaman SJ 1990 Reactivity of primary biliary cirrhosis sera with Escherichia coli dihydrolipoamide acetyltransferase (E2p): characterization of the main immunogenic region. Proc. Natl. Acad. Sci. U.S.A. 87: 3987-3991. *
Fussey SP, Bassendine MF, Fittes D, Turner IB, James OF, Yeaman SJ 1989 The E1 alpha and beta subunits of the pyruvate dehydrogenase complex are M2'd' and M2'e' autoantigens in primary biliary cirrhosis. Clin. Sci. (Lond.) 77: 365-368. *
Fussey SP, Guest JR, James OF, Bassendine MF, Yeaman SJ 1988 Identification and analysis of the major M2 autoantigens in primary biliary cirrhosis. Proc. Natl. Acad. Sci. U.S.A. 85: 8654-8658. *
Fussey SP, West SM, Lindsay JG, Ragan CI, James OF, Bassendine MF, Yeaman SJ 1991 Clarification of the identity of the major M2 autoantigen in primary biliary cirrhosis. Clin. Sci. (Lond.) 80: 451-455.
Gabeta S, Norman GL, Liaskos C, Papamichalis PA, Zografos T, Garagounis A, Rigopoulou EI, Dalekos GN 2007 Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J. Clin. Immunol. 27: 378-387. *
Galambos JT, Brooks WS Jr 1980 Atypical biliary cirrhosis - or sclerosing cholangitis. J. Clin. Gastroenterol. 2: 43-52.
Galperin C, Gershwin ME 1996 Immunopathology of primary biliary cirrhosis. Baillieres Clin. Gastroenterol. 10: 461-481.
Garcia Villarreal L, Zozaya JM, Macias E, Garcia Gonzalez N, Quiroga J, Conchillo F, Prieto J 1991 The treatment of primary biliary cirrhosis with ursodeoxycholic acid. The short- and median-term results and their relation to the study of the disease. Rev. Esp. Enferm. Dig. 80: 311-315.
Garcia-Ruiz C, Fernandez-Checa JC 2007 Redox regulation of hepatocyte apoptosis. J. Gastroenterol. Hepatol. 22 Suppl. 1: S38-S42.
Garcia-Ruiz I, Rodriguez-Juan C, Diaz-Sanjuan T, Del Hoyo P, Colina F, Munoz-Yague T, Solis-Herruzo JA 2006 Uric acid and anti-TNF antibody improve mitochondrial dysfunction in ob/ob mice. Hepatology 44: 581-591. *
Gatselis NK, Stefos A, Gioti C, Rigopoulou EI, Dalekos GN 2007 Primary biliary cirrhosis and Henoch-Schonlein purpura: report of two cases and review of the literature. Liver Int. 27: 280-283. *
Geetha A, Parameswari S 2002 Effect of ursodeoxycholic acid on hydrogen peroxide induced lipid peroxidation in sheep liver mitochondria. Indian J. Physiol. Pharmacol. 46: 343-348.
Gerber MA, Thung SN 1978 Ultrastructural localization of mitochondrial and ribosomal antigens by peroxidase-labeled human antibodies. Lab. Invest. 39: 101-105.
German OL, Insua MF, Gentili C, Rotstein NP, Politi LE 2006 Docosahexaenoic acid prevents apoptosis of retina photoreceptors by activating the ERK/MAPK pathway. J. Neurochem. 98: 1507-1520. *
Gershwin ME 2004 Primary biliary cirrhosis: from induction through destruction. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 39-40. *
Gershwin ME 2005 The immunopathology of primary biliary cirrhosis: unraveling the mystery of etiology. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 61. *
Gershwin ME, Ansari AA, Mackay IR, Nakanuma Y, Nishio A, Rowley MJ, Coppel RL 2000 Primary biliary cirrhosis: an orchestrated immune response against epithelial cells. Immunol. Rev. 174: 210-225. *
Gershwin ME, Leung PS, Li H, Seldin MF 2000 Primary biliary cirrhosis and autoimmunity: evaluating the genetic risk. Isr. Med. Assoc. J. 2 Suppl: 7-10.
Gershwin ME, Mackay IR 2008 The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 47: 737-745. *
Gershwin ME, Mackay IR 1991 Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 100: 822-833.
Gershwin ME, Mackay IR 1995 New knowledge in primary biliary cirrhosis. Hosp. Pract. (Off. Ed.) 30: 29-36.
Gershwin ME, Mackay IR, Sturgess A, Coppel RL 1987 Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J. Immunol. 138: 3525-3531.
Gershwin ME, Rowley M, Davis PA, Leung P, Coppel R, Mackay IR 1992 Molecular biology of the 2-oxo-acid dehydrogenase complexes and anti-mitochondrial antibodies. Prog. Liver Dis. 10: 47-61.
Gershwin ME, Van de Water J, Leung P, Ansari AA, Coppel RL 2003 The pathobiology and the cause of primary biliary cirrhosis. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 36-37. September 12 - 13. *
Gershwin ME, Van de WaterJ, Leung P, Ansari AA, Coppel RL 2003 Primary biliary cirrhosis: from induction through destruction. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 18. October 15-16. *
Ghadiminejad I, Baum H 1987 Reaction pattern of mitochondrial antibodies of primary biliary cirrhosis (PBC) is species specific but not organ specific. J. Bioenerg. Biomembr. 19: 239-253.
Ghadiminejad I, Baum H 1986 Discrimination between M2 and M4 antimitochondrial antibodies in primary biliary cirrhosis. Biosci. Rep. 6: 1049-1056.
Ghadiminejad I, Baum H 1987 Evidence for the cell-surface localization of antigens cross-reacting with the "mitochondrial antibodies" of primary biliary cirrhosis. Hepatology 7: 743-749.
Gheorghe L, Iacob S, Bolog N, Stoicescu A, Parvulescu I, Popescu I 2004 Overlap syndrome between autoimmune hepatitis and primary biliary cirrhosis complicated by hepatocellular carcinoma. Case report. Rom. J. Gastroenterol. 13: 33-38.
Ghezzi A, Zaffaroni M 2001 Neurological manifestations of gastrointestinal disorders, with particular reference to the differential diagnosis of multiple sclerosis. Neurol. Sci. 22 Suppl. 2: S117-S122.
Ghonaim M, Al-Ghamdi A, El-Bana H, Bakr A, Ghoneim E, El-Edel R, Hassona M, Shoeib S, Allam H 2005 Autoantibodies in chronic liver disease. Egypt. J. Immunol. 12: 101-111.
Gilbrud B, Weiss P, Bakimer R, Shoenfeld Y 1995 Identification and characterization of antimitochondrial autoantibodies in sera of patients with monoclonal gammopathies. Immunol. Lett. 45: 163-166.
Gilburd B, Ziporen L, Zharhary D, Blank M, Zurgil N, Scheinberg MA, Guedes LH, Gershwin ME, Shoenfeld Y 1994 Antimitochondrial (pyruvate dehydrogenase) antibodies in leprosy. J. Clin. Immunol. 14: 14-19.
Giorgini A, Selmi C, Invernizzi P, Podda M, Zuin M, Gershwin ME 2005 Primary biliary cirrhosis: solving the enigma. Ann. N. Y. Acad. Sci. 1051: 185-193. *
Gisbert JP, Jones EA, Pajares JM, Moreno-Otero R 2003 Review article: is there an optimal therapeutic regimen for antimitochondrial antibody-negative primary biliary cirrhosis (autoimmune cholangitis)? Aliment. Pharmacol. Ther. 17: 17-27. *
Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, Lugering N 2004 Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J. Immunol. 172: 5103-5109. *
Gogos CA, Nikolopoulou V, Zolota V, Siampi V, Vagenakis A 1999 Autoimmune cholangitis in a patient with celiac disease: a case report and review of the literature. J. Hepatol. 30: 321-324. *
Golovnova EV, Il'chenko LIu, Tsaregorodtseva TM, Serova TI, Gudkova RV, Shepeleva SD, Tkachev VD 2003 Primary biliary cirrhosis: 12-year experience in observation. Ter. Arkh. 75: 26-30.
Gong P, Cederbaum AI 2006 Nrf2 is increased by CYP2E1 in rodent liver and HepG2 cells and protects against oxidative stress caused by CYP2E1. Hepatology 43: 144-153. *
Gong Y, Gluud C 2005 Colchicine for primary biliary cirrhosis: a Cochrane hepato-biliary group systematic review of randomized clinical trials. Am. J. Gastroenterol. 100: 1-10. *
Gonzalez M, Ribalta J, Reyes H, Klinger J, Maggiolo P, Varleta P, Hernandez I, Delgado M, Donoso S 1990 Primary biliary cirrhosis. The clinical experience in 31 patients. Rev. Med. Chil. 118: 1350-1354.
Gonzalez-Huezo MS, Villela LM, Zepeda-Florencio Mdel C, Carrillo-Ponce CS, Mondragon-Sanchez RJ 2006 Nodular regenerative hyperplasia associated to aplastic anemia: a case report and literature review. Ann. Hepatol. 5: 166-169. *
Goodman ZD, McNally PR, Davis DR, Ishak KG 1995 Autoimmune cholangitis: a variant of primary biliary cirrhosis. Clinicopathologic and serologic correlations in 200 cases. Dig. Dis. Sci. 40: 1232-1242.
Goring HD, Panzner M, Lakotta W, Ziemer A 1998 Coincidence of scleroderma and primary biliary cirrhosis. Results of a systematic study of a dermatologic patient sample. Hautarzt. 49: 361-366.
Gouw AS, Haagsma EB, Manns M, Klompmaker IJ, Slooff MJ, Gerber MA 1994 Is there recurrence of primary biliary cirrhosis after liver transplantation? A clinicopathologic study in long-term survivors. J. Hepatol. 20: 500-507.
Grabacka M, Reiss K 2008 Anticancer properties of PPARalpha - effects on cellular metabolism and inflammation. PPAR Res. 2008: 930705. *
Graf D, Kurz AK, Reinehr R, Fischer R, Kircheis G, Haussinger D 2002 Prevention of bile acid-induced apoptosis by betaine in rat liver. Hepatology 36: 829-839. *
Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Ferri S, Quarneti C, Cipriano V, DE Molo C, Lenzi M, Chapman RW, Bianchi FB 2007 Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment. Pharmacol. Ther. 26: 831-838. *
Granito A, Muratori P, Muratori L, Pappas G, Cassani F, Worthington J, Guidi M, Ferri S, DE Molo C, Lenzi M, Chapman RW, Bianchi FB 2006 Antinuclear antibodies giving the 'multiple nuclear dots' or the 'rim-like/membranous' patterns: diagnostic accuracy for primary biliary cirrhosis. Aliment. Pharmacol. Ther. 24: 1575-1583. *
Gregorio GV, Portmann B, Mowat AP, Vergani D, Mieli-Vergani G 1997 A 12-year-old girl with antimitochondrial antibody-positive autoimmune hepatitis. J. Hepatol. 27: 751-754. *
Grimbert S, Johanet C, Bendjaballah F, Homberg JC, Poupon R, Beaugrand M 1996 Antimitochondrial antibodies in patients with chronic hepatitis C. Liver 16: 161-165.
Gruber R, Felber E, Pape GR, Hochtlen-Vollmar W, Riethmuller G 1994 Detection of autoantibodies against M2, LKM-1, and SLA in liver diseases by standardized uniform ELISA-techniques. J. Clin. Lab. Anal. 8: 284-292.
Grunewald RW, Fiedler GM, Stockmann F, Schauer A, Muller GA 1997 Unusual diagnosis in recurrent arthritis, erythema nodosum and arrhythmia. Dtsch. Med. Wochenschr. 122: 1516-1520.
Guedes Barbosa LS, Gilbrut B, Shoenfeld Y, Scheinberg MA 1996 Autoantibodies in leprosy sera. Clin. Rheumatol. 15: 26-28.
Gumpricht E, Dahl R, Devereaux MW, Sokol RJ 2005 Licorice compounds, glycyrrhizin and 18beta -glycyrrhetinic acid, are potent modulators of bile acid-induced cytotoxicity in rat hepatocytes. J. Biol. Chem. 280: 10556-10563. *
Gumpricht E, Dahl R, Devereaux MW, Sokol RJ 2004 Beta-carotene prevents bile acid-induced cytotoxicity in the rat hepatocyte: evidence for an antioxidant and anti-apoptotic role of beta-carotene in vitro. Pediatr. Res. 55: 814-821. *
Gundling F, Rohrbach H, Schepp W 2007 Cholestatic hepatitis in situs inversus abdominalis. Schweiz. Rundsch. Med. Prax. 96: 1029-1033.
Gupta R, Agarwal SR, Jain M, Malhotra V, Sarin SK 2001 Autoimmune hepatitis in the Indian subcontinent: 7 years experience. J. Gastroenterol. Hepatol. 16: 1144-1148. *
Gupta RC 1985 Specificities and characteristics of mitochondrial protein antigens assessed by enzyme linked immunosorbent assay for anti-mitochondrial antibodies. Relationship to immunofluorescent and precipitating antibodies. Clin. Exp. Immunol. 59: 604-612. *
Gupta RC, Dickson ER, McDuffie FC, Baggenstoss AH 1978 Circulating IgG complexes in primary biliary cirrhosis. A serial study in forty patients followed for two years. Clin. Exp. Immunol. 34: 19-27. *
Gupta RC, Seibold JR, Krishnan MR, Steigerwald JC 1984 Precipitating autoantibodies to mitochondrial proteins in progressive systemic sclerosis. Clin. Exp. Immunol. 58: 68-76. *
Gupta RC, Tan EM 1981 Isolation of circulating immune complexes by conglutinin and separation of antigen from dissociated complexes by immobilized protein A. Clin. Exp. Immunol. 46: 9-19. *
Gut J, Christen U, Huwyler J 1993 Mechanisms of halothane toxicity: novel insights. Pharmacol. Ther. 58: 133-155.
Guy J 2008 Optic nerve degeneration in experimental autoimmune encephalomyelitis. Ophthalmic Res. 40: 212-216.
Gvozdjakova A, Kucharska J, Bartkovjakova M, Gazdikova K, Gazdik FE 2005 Coenzyme Q10 supplementation reduces corticosteroids dosage in patients with bronchial asthma. Biofactors 25: 235-240.
Gyamfi MA, Kocsis MG, He L, Dai G, Mendy AJ, Wan YJ 2006 The role of retinoid X receptor alpha in regulating alcohol metabolism. J. Pharmacol. Exp. Ther. 319: 360-368. *
Haagsma EB, Manns M, Klein R, Grond J, Huizenga JR, Slooff MJ, Meyer zum Buschenfelde KH, Berg PA, Gips CH 1987 Subtypes of antimitochondrial antibodies in primary biliary cirrhosis before and after orthotopic liver transplantation. Hepatology 7: 129-133.
Haberhauer G, Wandner G, Machacek E, Broll H 1987 CRST syndrome and primary biliary cirrhosis. Z. Rheumatol. 46: 341-343.
Haitina T, Lindblom J, Renstrom T, Fredriksson R 2006 Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics 88: 779-790. *
Hall S, Axelsen PH, Larson DE, Bunch TW 1984 Systemic lupus erythematosus developing in patients with primary biliary cirrhosis. Ann. Intern. Med. 100: 388-389.
Hama K, Miwa H, Nishino I, Nonaka I, Kondo T 2004 Inclusion body myositis associated with chronic thyroiditis, Sjogren's syndrome and autoimmune cholangitis. No To Shinkei 56: 503-507.
Hamada M, Tokumoto Y, Furukawa S, Minami H, Hiasa Y, Michitaka K, Horiike N, Onji M 2004 Hepatopulmonary syndrome in a patient with primary biliary cirrhosis. Intern. Med. 43: 458-460. *
Han Y, Zhang W, Chen J, Zhou H, Wang L 2001 Clinical and pathological study of autoimmune hepatopathy. Zhonghua Gan Zang Bing Za Zhi 9: 82S-84S.
Hanson JC, Bostick MK, Campe CB, Kodali P, Lee G, Yan J, Maher JJ 2006 Transgenic overexpression of interleukin-8 in mouse liver protects against galactosamine/endotoxin toxicity. J. Hepatol. 44: 359-367. *
Harada K, Sudo Y, Kono N, Ozaki S, Tsuneyama K, Gershwin ME, Nakanuma Y 1999 In situ nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1alpha, BCOADC-E1alpha, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis. Hepatology 30: 36-45. *
Harada K, Van de Water J, Leung PS, Coppel RL, Nakanuma Y, Gershwin ME 1997 In situ nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium. Hepatology 25: 27-32. *
Haratake J, Kasai T, Makino H 2002 Diffuse mucosal carcinoma of intrahepatic and extrahepatic bile ducts including gallbladder. Pathol. Int. 52: 784-788. *
Harhaji L, Isakovic A, Vucicevic L, Janjetovic K, Misirkic M, Markovic Z, Todorovic-Markovic B, Nikolic N, Vranjes-Djuric S, Nikolic Z, Trajkovic V 2008 Modulation of tumor necrosis factor-mediated cell death by fullerenes. Pharm. Res. 25: 1365-1376. *
Hartel M, di Mola FF, Selvaggi F, Mascetta G, Wente MN, Felix K, Giese NA, Hinz U, Di Sebastiano P, Buchler MW, Friess H 2006 Vanilloids in pancreatic cancer: potential for chemotherapy and pain management. Gut 55: 519-528. *
Hashimoto E, Shimada M, Noguchi S, Taniai M, Tokushige K, Hayashi N, Takasaki K, Fuchinoue S, Ludwig J 2001 Disease recurrence after living liver transplantation for primary biliary cirrhosis: a clinical and histological follow-up study. Liver Transpl. 7: 588-595. *
Hashimoto E, Taniai M, Yatsuji S, Tokushige K, Shiratori K, Yamamoto M, Fuchinoue S 2007 Long-term clinical outcome of living-donor liver transplantation for primary biliary cirrhosis. Hepatol. Res. 37 Suppl. 3: S455-S461. *
Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS 2000 Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J. Biol. Chem. 275: 28918-28928. *
Hatano E, Tanaka A, Kanazawa A, Tsuyuki S, Tsunekawa S, Iwata S, Takahashi R, Chance B, Yamaoka Y 2004 Inhibition of tumor necrosis factor-induced apoptosis in transgenic mouse liver expressing creatine kinase. Liver Int. 24: 384-393. *
Hatzis GS, Fragoulis GE, Karatzaferis A, Delladetsima I, Barbatis C, Moutsopoulos HM 2008 Prevalence and longterm course of primary biliary cirrhosis in primary Sjogren's syndrome. J. Rheumatol. Aug 12 [Epub ahead of print].
Hayase Y, Iwasaki S, Akisawa N, Saibara T, Kadokawa Y, Omagari K, Maeda T, Onishi S 2005 Similar anti-mitochondrial antibody reactivity profiles in familial primary biliary cirrhosis. Hepatol. Res. 33: 33-38.
Hays SB, Camisa C 1985 Rendu-Osler-Weber-like telangiectasia associated with primary biliary cirrhosis. Cutis. 35: 152-153.
Hazama H, Omagari K, Masuda J, Kinoshita H, Ohba K, Sakimura K, Matsuo I, Isomoto H, Murase K, Murata I, Kohno S 2000 Serial changes in enzyme inhibitory antibody to pyruvate dehydrogenase complex during the course of primary biliary cirrhosis. J. Clin. Lab. Anal. 14: 208-213. *
Hazama H, Omagari K, Masuda J, Ohba K, Kinoshita H, Matsuo I, Isomoto H, Mizuta Y, Murase K, Murata I, Kohno S 2002 Automated enzymatic mitochondrial antibody assay for the diagnosis of primary biliary cirrhosis: applications of a routine diagnostic tool for the detection of antimitochondrial antibodies. J. Gastroenterol. Hepatol. 17: 316-323. *
Heathcote EJ 1998 Autoimmune cholangitis. Clin. Liver Dis. 2: 303-311, viii-ix.
Heathcote EJ 2003 Primary biliary cirrhosis: historical perspective. Clin. Liver Dis. 7: 735-740.
Heathcote EJ 2000 Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines. Hepatology 31: 1005-1013. *
Heathcote EJ 2003 Primary biliary cirrhosis. Clin. Liver Dis. 7: xi-xii. *
Heathcote EJ, Cauch-Dudek K, Walker V, Bailey RJ, Blendis LM, Ghent CN, Michieletti P, Minuk GY, Pappas SC, Scully LJ, et al 1994 The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 19: 1149-1156.
Heathcote J 2000 Update on primary biliary cirrhosis. Can. J. Gastroenterol. 14: 43-48.
Heathcote J 2001 Primary biliary cirrhosis with features of autoimmune hepatitis. Curr. Gastroenterol. Rep. 3: 60-64.
Heathcote J 2003 Overlap syndromes - outlier syndromes and changing diagnoses. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 39-41. October 15-16. *
Heininger K 2000 A unifying hypothesis of Alzheimer's disease. III. Risk factors. Hum. Psychopharmacol. 15: 1-70.
Hendrick AM, Mitchison HC, Bird AG, James OF 1986 Paraproteins in primary biliary cirrhosis. Q. J. Med. 60: 681-684.
Herrema H, Derks TG, van Dijk TH, Bloks VW, Gerding A, Havinga R, Tietge UJ, Muller M, Smit GP, Kuipers F, Reijngoud DJ 2008 Disturbed hepatic carbohydrate management during high metabolic demand in medium-chain acyl-CoA dehydrogenase (MCAD)-deficient mice. Hepatology 47: 1894-1904.
Herrine SK 2003 Drug-induced liver disease. 54th Annual Meeting of the American Association for the Study of Liver Diseases.
Heseltine L, Turner IB, Fussey SP, Kelly PJ, James OF, Yeaman SJ, Bassendine MF 1990 Primary biliary cirrhosis. Quantitation of autoantibodies to purified mitochondrial enzymes and correlation with disease progression. Gastroenterology 99: 1786-1792.
Heyman SN, Spectre G, Aamar S, Rubinger D, Pappo O, Ackerman Z 2002 Autoimmune cholangiopathy associated with systemic lupus erythematosus. Liver 22: 102-106.
Higami Y, Tsuchiya T, Chiba T, Yamaza H, Muraoka I, Hirose M, Komatsu T, Shimokawa I 2006 Hepatic gene expression profile of lipid metabolism in rats: impact of caloric restriction and growth hormone/insulin-like growth factor-1 suppression. J. Gerontol. A. Biol. Sci. Med. Sci. 61: 1099-1110.
Higuchi H, Miyoshi H, Bronk SF, Zhang H, Dean N, Gores GJ 2001 Bid antisense attenuates bile acid-induced apoptosis and cholestatic liver injury. J. Pharmacol. Exp. Ther. 299: 866-873. *
Hirakata M, Akizuki M, Miyachi K, Matsushima H, Okano T, Homma M 1988 Coexistence of CREST syndrome and primary biliary cirrhosis. Serological studies of two cases. J. Rheumatol. 15: 1166-1170.
Hiraoka A, Kojima N, Yamauchi Y, Ninomiya T, Masumoto T, Michitaka K, Horiike N, Onji M 2001 An autopsy case of primary biliary cirrhosis with severe interstitial pneumonia. Intern. Med. 40: 1104-1108. *
Hirschfield GM, Heathcote EJ 2008 Antimitochondrial antibody-negative primary biliary cirrhosis. Clin. Liver Dis. 12: 323-331.
Hoffman M, Burke M, Fried M, Turner D, Yosipov Y, Yust I 1997 Primary biliary cirrhosis associated with antiphospholipid syndrome. Isr. J. Med. Sci. 33: 681-686.
Hoffmann R, Germann EJ, Schmidt U, Jenss H 1986 Primary biliary liver cirrhosis and granulomatous pulmonary infiltrates. Schweiz. Med. Wochenschr. 116: 1098-1102.
Hoffmann U, Heilmann K, Hayford C, Stallmach A, Wahnschaffe U, Zeitz M, Gunthert U, Wittig BM 2007 CD44v7 ligation downregulates the inflammatory immune response in Crohn's disease patients by apoptosis induction in mononuclear cells from the lamina propria. Cell Death Differ. 14: 1542-1551.
Hofmanova J, Vaculova A, Hyzd'alova M, Kozubik A 2008 Response of normal and colon cancer epithelial cells to TNF-family apoptotic inducers. Oncol. Rep. 19: 567-573.
Hoglen NC, Hirakawa BP, Fisher CD, Weeks S, Srinivasan A, Wong AM, Valentino KL, Tomaselli KJ, Bai X, Karanewsky DS, Contreras PC 2001 Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. J. Pharmacol. Exp. Ther. 297: 811-818. *
Hokari A, Zeniya M, Esumi H, Kawabe T, Gershwin ME, Toda G 2002 Detection of serum nitrite and nitrate in primary biliary cirrhosis: possible role of nitric oxide in bile duct injury. J. Gastroenterol. Hepatol. 17: 308-315. *
Hollingsworth KG, Newton JL, Taylor R, McDonald C, Palmer JM, Blamire AM, Jones DE 2008 Pilot study of peripheral muscle function in primary biliary cirrhosis: potential implications for fatigue pathogenesis. Clin. Gastroenterol. Hepatol. Aug 6 [Epub ahead of print].
Holt KM, Miyai K, Chojkier M 1986 Asymptomatic primary biliary cirrhosis in an old man. J. Clin. Gastroenterol. 8: 203-206.
Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, Poupon R, Darnis F, Levy VG, Grippon P, et al 1987 Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 7: 1333-1339.
Honma F, Shio K, Monoe K, Kanno Y, Takahashi A, Yokokawa J, Kobayashi H, Watanabe H, Irisawa A, Ohira H 2008 Primary biliary cirrhosis complicated by polymyositis and pulmonary hypertension. Intern. Med. 47: 667-669. *
Hopf U, Jahn HU, Moller B, Stemerowicz R, Wittenbrink C, Klein R, Berg PA 1990 Liver membrane antibodies (LMA) recognize a 26-kD protein on the hepatocellular surface. Clin. Exp. Immunol. 79: 54-61. *
Hopf U, Moller B, Lobeck H, Klein R, Berg PA 1985 Immunoserologic differentiation of chronic cholestatic hepatitis. Significance of antimitochondrial antibodies and hepatic membrane antibodies. Dtsch. Med. Wochenschr. 110: 1924-1929.
Hopf U, Moller B, Stemerowicz R, Lobeck H, Rodloff A, Freudenberg M, Galanos C, Huhn D 1989 Relation between Escherichia coli R(rough)-forms in gut, lipid A in liver, and primary biliary cirrhosis. Lancet 2: 1419-1422.
Hopf U, Riecken EO, Zeitz M, Eckhardt R, Lobeck H, Malchus R, Moller B 1983 Immunologic parameters in pericholangitis and primary sclerosing cholangitis with and without ulcerative colitis. Dtsch. Med. Wochenschr. 108: 1515-1521.
Hopf U, Stemerowicz R, Knigge O, Khadar R, Konig V, Lobeck H, Neuhaus P 1993 Primary sclerosing cholangitis (PSC) - humoral immune phenomena, pathogenetic aspects and therapeutic possibilities. Z. Gastroenterol. 31 Suppl. 2: 106-10.
Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H 2004 Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J. Hepatol. 41: 1008-1016. *
Horigome H, Nomura T, Saso K, Joh T, Ohara H, Akita S, Sobue S, Mizuno Y, Kato Y, Itoh M 2000 Coexistence of primary biliary cirrhosis and myasthenia gravis: a case study. Hepatogastroenterology 47: 125-127.
Horsmans Y, Piret A, Brenard R, Rahier J, Geubel AP 1994 Autoimmune chronic active hepatitis responsive to immunosuppressive therapy evolving into a typical primary biliary cirrhosis syndrome: a case report. J. Hepatol. 21: 194-198.
Hosoda H, Okawa-Takatsuji M, Tanaka A, Uwatoko S, Aotsuka S, Hasimoto N, Ozaki Y, Ikeda Y 2004 Detection of autoantibody against carbonic anhydrase II in various liver diseases by enzyme-linked immunosorbent assay using appropriate conditions. Clin. Chim. Acta 342: 71-81. *
Hosokawa A, Takahashi H, Akaike J, Okuda H, Murakami R, Kawahito Y, Tokuno T, Makiguchi Y, Sakamoto H, Hinoda Y, Imai K 1998 A case of Sjogren's syndrome associated with inflammatory pseudotumor of the liver. Nihon Rinsho Meneki Gakkai Kaishi 21: 226-233.
Hosseini-Tabatabaei A, Abdollahi M 2008 Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm. Allergy Drug Targets 7: 129-135.
Houston MC 2007 The role of mercury and cadmium heavy metals in vascular disease, hypertension, coronary heart disease, and myocardial infarction. Altern. Ther. Health Med. 13: S128-S133.
Howard MJ, Fuller C, Broadhurst RW, Perham RN, Tang JG, Quinn J, Diamond AG, Yeaman SJ 1998 Three-dimensional structure of the major autoantigen in primary biliary cirrhosis. Gastroenterology 115: 139-146. *
Hsieh SY, Shih TC, Yeh CY, Lin CJ, Chou YY, Lee YS 2006 Comparative proteomic studies on the pathogenesis of human ulcerative colitis. Proteomics 6: 5322-5331. *
Huang RH, Chai J, Tarnawski AS 2006 Identification of specific genes and pathways involved in NSAIDs-induced apoptosis of human colon cancer cells. World J. Gastroenterol. 12: 6446-6452. *
Hug B, Fried R, Terracciano L 1998 Pruritus in liver disease: case report with discussion. Schweiz. Rundsch. Med. Prax. 87: 1805-1810.
Hughes DE, Stolz DB, Yu S, Tan Y, Reddy JK, Watkins SC, Diehl AM, Costa RH 2003 Elevated hepatocyte levels of the Forkhead box A2 (HNF-3beta) transcription factor cause postnatal steatosis and mitochondrial damage. Hepatology 37: 1414-1424. *
Hulbert AJ, Else PL 2005 Membranes and the setting of energy demand. J. Exp. Biol. 208: 1593-1599. *
Hulbert AJ, Faulks SC, Buffenstein R 2006 Oxidation-resistant membrane phospholipids can explain longevity differences among the longest-living rodents and similarly-sized mice. J. Gerontol. A. Biol. Sci. Med. Sci. 61: 1009-1018.
Hung HC, Lin CY, Liao YF, Hsu PC, Tsay GJ, Liu GY 2007 The functional haplotype of peptidylarginine deiminase IV (S55G, A82V and A112G) associated with susceptibility to rheumatoid arthritis dominates apoptosis of acute T leukemia Jurkat cells. Apoptosis 12: 475-487. *
Hurlburt KJ, McMahon BJ, Deubner H, Hsu-Trawinski B, Williams JL, Kowdley KV 2002 Prevalence of autoimmune liver disease in Alaska Natives. Am. J. Gastroenterol. 97: 2402-2407. *
Husby G, Skrede S, Blomhoff JP, Jacobsen CD, Berg K, Gjone E 1977 Serum immunoglobulins and organ non-specific antibodies in diseases of the liver. Scand. J. Gastroenterol. 12: 297-304.
Hussaini SH, Farrington EA 2007 Idiosyncratic drug-induced liver injury: an overview. Expert Opin. Drug Saf. 6: 673-684.
Hwang SJ, Chan CY, Lee SD, Wu JC, Tsay SH, Lo KJ 1993 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a short-term, randomized, double-blind controlled, cross-over study with long-term follow up. J. Gastroenterol. Hepatol. 8: 217-223.
Ibdah JA, Perlegas P, Zhao Y, Angdisen J, Borgerink H, Shadoan MK, Wagner JD, Matern D, Rinaldo P, Cline JM 2005 Mice heterozygous for a defect in mitochondrial trifunctional protein develop hepatic steatosis and insulin resistance. Gastroenterology 128: 1381-1390. *
Ichiki Y, Leung PS, Ishibashi H, Coppel RL, Ansari AA, Gershwin ME 2004 Mitochondria and autoimmunity in primary biliary cirrhosis. Mitochondrion 4: 743-753.
Ichiki Y, Selmi C, Shimoda S, Ishibashi H, Gordon SC, Gershwin ME 2005 Mitochondrial antigens as targets of cellular and humoral auto-immunity in primary biliary cirrhosis. Clin. Rev. Allergy Immunol. 28: 83-92. *
Ida H, Utz PJ, Anderson P, Eguchi K 2005 Granzyme B and natural killer (NK) cell death. Mod. Rheumatol. 15: 315-322.
Ide T, Sata M, Suzuki H, Uchimura Y, Murashima S, Shirachi M, Tanikawa K 1996 An experimental animal model of primary biliary cirrhosis induced by lipopolysaccharide and pyruvate dehydrogenase. Kurume. Med. J. 43: 185-188.
Ikeda Y, Toda G, Hashimoto N, Aotsuka S, Yokohari R, Maruyama T, Oka H 1987 Anticalmodulin autoantibody in liver diseases: a new antibody against a cytoskeleton-related protein. Hepatology 7: 285-293.
Ikuno N, Mackay IR, Jois J, Omagari K, Rowley MJ 2001 Antimitochondrial autoantibodies in saliva and sera from patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 16: 1390-1394. *
Il'ichenko LIu, Golovanova EV, Tsaregorodtseva TM, Serova TI, Gudkova RB 2005 Current understanding of primary biliary cirrhosis. Ter. Arkh. 77: 50-54.
Ilan Y, Shouval D 1992 Primary biliary cirrhosis in Israel. Isr. J. Med. Sci. 28: 683-687.
Imada J, Hoshino H, Nishimura D, Morita K, Yoshida N, Katada N, Sano H, Kato K, Mori N 1996 Case report: multiple cancers: hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 11: 546-550.
Imose M, Nagaki M, Naiki T, Osawa Y, Brenner DA, Asano T, Hayashi H, Kato T, Moriwaki H 2003 Inhibition of nuclear factor kappaB and phosphatidylinositol 3-kinase/Akt is essential for massive hepatocyte apoptosis induced by tumor necrosis factor alpha in mice. Liver Int. 23: 386-396. *
Inamura K,Tsuji H, Nakamoto Y, Suzuki M, Kaneko S 2006 Transgenic mice aberrantly expressing pyruvate dehydrogenase complex E2 component on biliary epithelial cells do not show primary biliary cirrhosis. Clin. Exp. Immunol. 145: 93-100. *
Inbar Y, Zurgil N, Gilburt C, Shoenfeld Y 1993 Antimitochondrial antibodies and primary biliary cirrhosis. Harefuah. 125: 148-152.
Inoue K, Hirohara J, Nakano T, Seki T, Sasaki H, Higuchi K, Ohta Y, Onji M, Muto Y, Moriwaki H 1995 Prediction of prognosis of primary biliary cirrhosis in Japan. Liver 15: 70-77.
Inoue T, Shiraki K, Fuke H, Yamanaka Y, Miyashita K, Ito K, Suzuki M, Sugimoto K, Murata K, Nakano T 2005 A case report of primary biliary cirrhosis after aortoiliac reconstruction surgery using a Y-graft. World J. Gastroenterol. 11: 6219-6220. *
Invernizzi P 2007 Role of X chromosome defects in primary biliary cirrhosis. Hepatol. Res. 37 Suppl. 3: S384-S388. *
Invernizzi P, Battezzati PM, Crosignani A, Perego F, Poli F, Morabito A, De Arias AE, Scalamogna M, Zuin M, Podda M 2003 Peculiar HLA polymorphisms in Italian patients with primary biliary cirrhosis. J. Hepatol. 38: 401-406. *
Invernizzi P, Battezzati PM, Crosignani A, Zermiani P, Bignotto M, Del Papa N, Zuin M, Podda M 1998 Antibody to carbonic anhydrase II is present in primary biliary cirrhosis (PBC) irrespective of antimitochondrial antibody status. Clin. Exp. Immunol. 114: 448-454. *
Invernizzi P, Crosignani A, Battezzati PM, Covini G, De Valle G, Larghi A, Zuin M, Podda M 1997 Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 25: 1090-1095. *
Invernizzi P, Invernizzi P, Gershwin ME 2008 The genetic basis of primary biliary cirrhosis: premises, not promises. Gastroenterology Sep 3 [Epub ahead of print]. *
Invernizzi P, Podda M, Battezzati PM, Crosignani A, Zuin M, Hitchman E, Maggioni M, Meroni PL, Penner E, Wesierska-Gadek J 2001 Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J. Hepatol. 34: 366-372. *
Invernizzi P, Selmi C, Ranftler C, Podda M, Wesierska-Gadek J 2005 Antinuclear antibodies in primary biliary cirrhosis. Semin. Liver Dis. 25: 298-310.
Invernizzi P, Selmi C, Zuin M, Podda M 2005 Lack of serum antibodies to membrane bound carbonic anhydrase IV in patients with primary biliary cirrhosis. Gut 54: 1665. *
Irie J, Wu Y, Wicker LS, Rainbow D, Nalesnik MA, Hirsch R, Peterson LB, Leung PS, Cheng C, Mackay IR, Gershwin ME, Ridgway WM 2006 NOD.c3c4 congenic mice develop autoimmune biliary disease that serologically and pathogenetically models human primary biliary cirrhosis. J. Exp. Med. 203: 1209-1219. *
Ishibashi H, Shimoda S, Gershwin ME 2005 The immune response to mitochondrial autoantigens. Semin. Liver Dis. 25: 337-346.
Ishigami F, Naka S, Takeshita K, Kurumi Y, Hanasawa K, Tani T 2001 Bile salt tauroursodeoxycholic acid modulation of Bax translocation to mitochondria protects the liver from warm ischemia-reperfusion injury in the rat. Transplantation 72: 1803-1807.
Ishii H, Muno D, Namihisa T 1989 Electrophoretic studies of antimitochondrial antibodies: identification of mitochondrial antigens specific to primary biliary cirrhosis. Electrophoresis 10: 612-618.
Ishii H, Saifuku K, Namihisa T 1985 Multiplicity of mitochondrial inner membrane antigens from beef heart reacting with antimitochondrial antibodies in sera of patients with primary biliary cirrhosis. Immunol. Lett. 9: 325-330.
Ishii H, Saifuku K, Namihisa T 1987 Reactivities and clinical relevance of antimitochondrial antibodies to four mitochondrial inner membrane proteins in sera of patients with primary biliary cirrhosis. Hepatology 7: 134-136.
Ishikawa T, Kakumu S, Wakita T, Takayanagi M, Yoshioka K 1991 In vitro production of antimitochondrial antibody by peripheral blood mononuclear cells in patients with primary biliary cirrhosis. J. Clin. Lab. Immunol. 35: 17-25.
Ito Y, Yamanoshita O, Kurata Y, Kamijima M, Aoyama T, Nakajima T 2007 Induction of peroxisome proliferator-activated receptor alpha (PPARalpha)-related enzymes by di(2-ethylhexyl) phthalate (DEHP) treatment in mice and rats, but not marmosets. Arch. Toxicol. 81: 219-226. *
Itoh S, Ichida T, Yoshida T, Hayakawa A, Uchida M, Tashiro-Itoh T, Matsuda Y, Ishihara K, Asakura H 1998 Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J. Gastroenterol. Hepatol. 13: 257-265.
Itoh S, Matsuzaki Y, Kimura T, Ikegami T, Shoda J, Fujiwara M, Tanaka N 2000 Cytokine profile of liver-infiltrating CD4+ T cells separated from murine primary biliary cirrhosis-like hepatic lesions induced by graft-versus-host reaction. J. Gastroenterol. Hepatol. 15: 443-451. *
Iwasaki S, Tsuda K, Ueta H, Aono R, Ono M, Saibara T, Maeda T, Onishi S 1999 Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis. Hepatol. Res. 16: 12-18.
Iwayama T, Leung PS, Rowley M, Munoz S, Nishioka M, Nakagawa T, Dickson ER, Coppel RL, Mackay IR, Gershwin ME 1992 Comparative immunoreactive profiles of Japanese and American patients with primary biliary cirrhosis against mitochondrial autoantigens. Int. Arch. Allergy Immunol. 99: 28-33.
Izumi Y, Tanaka S, Hidaka Y, Shimaoka Y, Tatsumi KI, Takano T, Kaneko A, Oku K, Amino N 2003 Relation between post-partum liver dysfunction and anti-cytochrome 2D6 antibodies. Am. J. Reprod. Immunol. 50: 355-362.
James LP, Mayeux PR, Hinson JA 2003 Acetaminophen-induced hepatotoxicity. Drug Metab. Dispos. 31: 1499-1506. *
James O, Macklon AF, Watson AJ 1981 Primary biliary cirrhosis - a revised clinical spectrum. Lancet 1: 1278-1281.
Jang JY, Choi Y, Jeon YK, Kim CW 2008 The suppression of adenine nucleotide translocase-2 (ANT2) by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo. Breast Cancer Res. 10: R11.
Jefcoate CR 2006 Liver X receptor opens a new gateway to StAR and to steroid hormones. J. Clin. Invest. 116: 1832-1835. *
Jensen WA, Jois JA, Murphy P, De Giorgio J, Brown B, Rowley MJ, Mackay IR 2000 Automated enzymatic mitochondrial antibody assay for the diagnosis of primary biliary cirrhosis. Clin. Chem. Lab. Med. 38: 753-758.
Jiang XH, Zhong RQ, Yu SQ, Hu Y, Li WW, Kong XT 2003 Construction and expression of a humanized M2 autoantigen trimer and its application in the diagnosis of primary biliary cirrhosis. World J. Gastroenterol. 9: 1352-1355. *
Jin X, Zimmers TA, Perez EA, Pierce RH, Zhang Z, Koniaris LG 2006 Paradoxical effects of short- and long-term interleukin-6 exposure on liver injury and repair. Hepatology 43: 474-484. *
Johannesen J 2006 Aspects of the molecular and functional genetics in T1DM - a study of selected candidate genes. Dan. Med. Bull. 53: 122-171.
Johnston DE, Kaplan MM, Miller KB, Connors CM, Milford EL 1987 Histocompatibility antigens in primary biliary cirrhosis. Am. J. Gastroenterol. 82: 1127-1129.
Jois J, Omagari K, Rowley MJ, Anderson J, Mackay IR 2000 Enzyme inhibitory antibody to pyruvate dehydrogenase: diagnostic utility in primary biliary cirrhosis. Ann. Clin. Biochem. 37: 67-73.
Jones DE 2000 Autoantigens in primary biliary cirrhosis. J. Clin. Pathol. 53: 813-821. *
Jones DE, James OF, Bassendine MF 1998 Primary biliary cirrhosis: clinical and associated autoimmune features and natural history. Clin. Liver Dis. 2: 265-282, viii.
Jones DE, Palmer JM, Kirby JA, De Cruz DJ, McCaughan GW, Sedgwick JD, Yeaman SJ, Burt AD, Bassendine MF 2000 Experimental autoimmune cholangitis: a mouse model of immune-mediated cholangiopathy. Liver 20: 351-356.
Jong-Hon K, Yajima R, Karino Y, Yoshida J, Tsuji K, Watanabe S, Horada K, Itoh Y, Sekiguchi K, Toyoda S, Maekubo H 2001 Development of a new enzyme-linked immunosorbent assay for the detection of anti-M2 in primary biliary cirrhosis. Hepatol. Res. 21: 1-7.
Joo Y, Kim HS, Woo RS, Park CH, Shin KY, Lee JP, Chang KA, Kim S, Suh YH 2006 Mefenamic acid shows neuroprotective effects and improves cognitive impairment in in vitro and in vivo Alzheimer's disease models. Mol. Pharmacol. 69: 76-84. *
Joplin R 2003 Infectious etiology of primary biliary cirrhosis? Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper�s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 19-20. October 15-16. *
Joplin R, Gershwin ME 1997 Ductular expression of autoantigens in primary biliary cirrhosis. Semin. Liver Dis. 17: 97-103.
Joplin R, Lindsay JG, Hubscher SG, Johnson GD, Shaw JC, Strain AJ, Neuberger JM 1991 Distribution of dihydrolipoamide acetyltransferase (E2) in the liver and portal lymph nodes of patients with primary biliary cirrhosis: an immunohistochemical study. Hepatology 14: 442-447.